Lists of funding opportunities are updated weekly. New funding opportunities for scientists are distributed in the VPRI Update newsletter.
To submit funding opportunities, and/or be added to the VPRI Update mailing list, please send your request to VPRI@smh.ca.
Opportunities are categorized by Sponsor Type (Tri-Agency, Other Canadian, International & NIH). Filter opportunities by keyword (e.g. Sponsor Type, CIHR, user-supplied keyword, etc.) using the Search box at right.
|Sponsor Type||Funding Program Title||Amount and Duration||Description||Deadline|
|Tri-Agency||CIHR Pre-Announcement: Cafe Scientifique Program||Up to $6,000 for 1 year. A supplement of $2,000 per grant is available for applications that demonstrate meaningful engagement and co-creation with knowledge users, patients, Indigenous communities and person(s) with lived/living experience.||CIHR will provide funding to design and deliver events known as Cafés that enable knowledge sharing and open, respectful dialogues between the general public and health research experts on health-related issues of public interest. Please see the pre-announcement for relevant research areas.||Anticipated Timelines:
Launch: Fall 2022
Application: Winter 2023
|Tri-Agency||CIHR Pre-Announcement: National Women's Health Research Initiative: Pan-Canadian Women's Health Coalition||It is anticipated that $9.6M will be allocated to the National Women's Health Research Initiative: Pan-Canadian Women's Health Coalition.||The Coalition will be composed of virtual hubs across Canada linked through a coordinating centre. The hubs and the coordinating centre will work together collectively to maximize the visibility and impact of women's health research and practice in Canada by committing to the principles of equity, diversity, inclusion, and Indigenous Rights. Applications for the hubs and coordinating centre will occur through two separate funding opportunities.||Anticipated Timelines:
Coordinating Centre: Launch: Fall 2023.
|Tri-Agency||CIHR Upcoming Funding Opportunity: Healthy Cities Research Initiative (HCRI) Planning Grants for Implementing Healthy Urban Policy||Up to $65,000 for 1 year to partake in the Urban Policy Workshop: $40,000 for registration and travel costs, and $25,000 for planning and knowledge mobilization activities.||This supports collaboration between city leaders and researchers and co-development of activities related to implementing and evaluating interventions in urban settings that would improve health and wellbeing. The goal of this funding opportunity is to facilitate the design of implementation research projects that could possibly be funded in the future.||Anticipated Timelines:
Launch: October 15, 2022
Application deadline: December 14, 2022
|Tri-Agency||CIHR Pre-Announcement: Team Grants: Intervention Trial in Inflammation for Chronic Conditions - Evidence to Impact||Letter of Intent: Up to $20,000 for 1 year; Research Team Grant: Up to $500,000 per year for up to 4 years; Knowledge Mobilization Hub: Up to $145,000 per year for up to 4 years.||This will support intervention trials in humans with clinical impact on inflammation in chronic conditions and lead to greater availabilities of solutions and catalyze change in clinical practice and policy. This research will support clinical, behavioral, socio-structural and/or environmental interventions related to inflammation in chronic conditions in humans to ultimately support the optimization of healthcare delivery.||Anticipated Timeline:
Letter of Intent: November 2022
Full Application (by invitation): December 2023
|Tri-Agency||CIHR Pre-Announcement: Health System Impact (HSI) Program||Please see individual funding opportunity description.||This provides highly qualified PhD trainees, postdoctoral researchers, and (new!) early career researchers in health services and policy research/related fields with the opportunity to develop embedded research projects/programs that address the most pressing problems faced by health system organizations and to support evidence-informed decision-making. The HSI Program will launch as two independent funding opportunities:|
- Health System Impact Fellowship: PhD & Postdoctoral Fellow Streams: Doctoral Fellows receive a one-year experiential learning opportunity where they are embedded in their health system partner organization for at least 60% of their time focused on an impact-oriented project of direct relevance to their partner organization. Postdoctoral Fellows receive a two-year experiential learning opportunity where they are embedded in their health system partner organization for at least 70% of their time focused on their impact-oriented program of work. Value: Doctoral: $50,000 per year for 1 year; Postdoctoral: $155,000 total for 2 years.
- Health System Impact Early Career Embedded Researcher Stream: Provides a four-year award to establish a career pathway for embedded ECRs, increase their potential for impact and contribution as embedded scholars. Through this 4-year award, ECRs are embedded within a health system organization for 60% of their time. Value: $400,000 total for 4 years.
Health System Impact Fellowship Information Webinar for Applicants: December 21, 2022 (12:00-1:00pm ET). Register here.
Applications Due: Winter 2023
Health System Impact Early Career Embedded Researcher Stream Information Webinar for Applicants: January 31, 2023 (12:00-1:00 pm ET). Register here.
Applications Due: Spring 2023
*These timelines are estimates and subject to change.
|Tri-Agency||NSERC/SSHRC Indigenous Scholars Awards and Supplements Pilot Initiative||$17,500 award and $5,000 supplement for 12 months.||Offered by NSERC and SSHRC, this will provide financial support to meritorious Indigenous students who have applied to the Canada Graduate Scholars-Master's program (CGS M). Applicants will leverage the same application form and follow the same application process as for the CGS M competition. For questions, email NSERC's scholarships division at email@example.com or SSHRC's Research Training Portfolio at firstname.lastname@example.org.||December 1, 2022.|
|Tri-Agency||CIHR Other: Network Grants in Skin Health, Bone Health, and Muscular Dystrophy||Up to $400,000 per year for up to 5 years.||This will provide support to create three networks: one in the area of Skin Health, one in the area of Bone Health and one in the area of Muscular Dystrophy. The aim of these networks will be to provide research leadership, stimulate innovative research and practices, strengthen research capacity, and provide a forum that engages the research community and its partners (including but not limited to industry, charities, and patients and their carers). The networks are expected to be national in scope, multidisciplinary and multi-thematic; and to foster collaborations, effective interactions, and scientific excellence.||Registration: December 1, 2022.
Application: January 17, 2023.
|Tri-Agency||CIHR Other: National Women's Health Research Initiative: Pan-Canadian Women's Health Coalition - Hubs||Up to $210,000 per year for up to 4 years.||Each hub must identify one or more areas of women's health to address, within the scope of this funding opportunity, based on community, regional and/or national needs, ensuring that women's and gender-diverse people's voices are at the heart of the hub's activities. Each hub requires tripartite leadership, including a non-governmental community organization, an independent researcher, and a healthcare provider, all in the area of women's health. Applicants to this funding opportunity are encouraged to attend the virtual Ideas Fair and Learning Circle event on October 25-26, 2022, from 12:00 - 4:00 pm EST.||Registration: December 14, 2022.
Application: February 1, 2023.
|Tri-Agency||SSHRC Partnership Engage Grants||Between $7,000 and $25,000.||These grants provide short-term and timely support for partnered research activities that will inform decision-making at a single partner organization from the public, private or not-for-profit sector.||December 15, 2022.|
|Tri-Agency||SSHRC Knowledge Synthesis Grants: Shifting Dynamics of Privilege and Marginalization||$30,000 for 1 year||This call for proposals focuses on the state of research knowledge on issues related to increasing global uncertainty and social volatility, and potential significant and diverse transformations for Canada and the world. The resulting syntheses will help to identify roles that the academic, public, private, and not-for-profit sectors may play in promoting more inclusive communities, as well as to inform the development of effective tools, robust policies and sustainable practices required to support the transition to a more cohesive and just future. Genome Canada has also joined SSHRC as a funding partner for this call and is seeking social sciences and humanities insights on issues related to genomics.||December 15, 2022.|
|Tri-Agency||CIHR Operating Grant: Summer Program in Aging - Planning Grant||$100,000. The SPA host will also receive a registration fee of $500/trainee.||The intent of this funding opportunity is to identify a host for the 2024 CIHR Institute of Aging's (IA) Summer Program in Aging (SPA). The SPA 2024 strategic topic area will be ageism, health, and older adults. The host of SPA 2024 will:|
- Develop the program and curriculum for an advanced training program for graduate students and postdoctoral fellows on the topic of ageism, health, and older adults
- Recruit and lead a planning and coordination team for SPA 2024
- Coordinate and manage the logistics related to the successful implementation of the SPA 2024 program
|December 21, 2022.|
|Tri-Agency||Tri-Council Special Response Fund for Trainees Ukraine (SRFT-Ukraine)||Master's level: Up to $20,000; Doctoral level: Up to $25,000; Postdoctoral level: Up to $45,000. Support can be requested for a period of up to 12 months. Requested amounts will be pro-rated to reflect the expected duration of the support.||This limited-time fund is to initiate or maintain the employment or financial support of trainees who are directly impacted by the crisis in Ukraine. CIHR- NSERC- and SSHRC-funded grant holders can apply. This additional funding for grant holders will support trainees, defined as graduate students or postdoctoral researchers through salaries and stipends.||Continuous intake until December 22, 2022.|
|Tri-Agency||CIHR Team Grant: Pan-Canadian Human Genome Library||Up to $3,000,000 per year for up to 5 years.||The specific objectives of this funding opportunity are to:|
- Develop a federated pan-Canadian framework that will enable access to and analysis of genomes and associated health/environmental information, governed in a transparent, accountable and consistent way;
- Address equity, diversity and inclusion by capturing the Canadian genomic "variome" to truly represent the richness of the genomic diversity of people living in Canada, and in all its diversity by promoting the inclusion of detailed information on key identity characteristics, such as sex, gender, and other intersecting identity factors, that shape the health of all people living in Canada;
- Position the framework as a key mechanism to improve effectiveness - both from an economic and health perspective - of healthcare delivery in a learning health system context;
- Provide means and opportunities to facilitate clinical trials that are increasingly based on genomic medicine;
- Position Canada as a key player in international genomic research endeavours.
|Letter of Intent: January 12, 2023.
Application: June 13, 2023.
|Tri-Agency||CIHR Other: Joint Canada-Israel Health Research Program||Up to $1.4 million for up to 4 years.||This for proposals from research teams led by Canadian, Israeli and low-and middle-income country investigators in the field of Communicable Diseases, with a particular focus on investigating underlying biological mechanisms and impacts on global health. Potential topics may include, but are not limited to, the following: Discovery research to identify new pathogens and their distribution in human populations; New therapeutic approaches for communicable diseases; Drug resistance biology and mechanism in infectious disease; Host - Parasite interactions; New directions in vaccine research for infectious diseases; New biomarkers for infectious disease detection, characterization and monitoring; Vector-borne and zoonotic diseases, including the impact of climate change on zoonotic disease distribution; New technology platforms for rapid detection of pathogens of pandemic importance.|
Exclusions: SARS-CoV-2 / COVID-19 research, studies, surveys, clinical trials and work primarily aimed at informing public health policy are NOT eligible for funding through this opportunity. However, the use of randomization in basic biomedical research studies is accepted.
|Registration Deadline: January 17, 2023 in Canada; January 17, 2023 in Israel.
Application Deadline: February 16, 2023 in Canada; February 15, 2023 in Israel.
|Tri-Agency||CIHR Other: CIHR-IMHA Inclusive Research Excellence Prizes||$25,000 for 1 year.||This funding opportunity seeks to reward research excellence achieved in the broad IMHA mandate areas by awarding prizes in the form of a supplemental grant to support further research. These will be given to investigators (individual or individuals) who have completed projects or programs of research in any of the 5 following domains: Research Impact; Team Science; Open Science; Patient Engagement; Indigenous Health Research.||Registration: January 26, 2023.
Application: February 23, 2023.
|Tri-Agency||CIHR Operating Grant: Evaluation of population-level interventions to reduce AMR||Up to $150,000 per year for up to 2 years.||This funding opportunity will support projects evaluating domestic or international population-level interventions to reduce inappropriate antimicrobial use and prevent the spread of resistant pathogens in humans, animals and the environment. Interventions being evaluated could fall into, but are not limited to: regulatory interventions, guideline interventions, communication interventions, legislation interventions, service provision interventions, environmental/social planning interventions, fiscal interventions.||February 2, 2023.|
|Tri-Agency||SSHRC Insight Development Grants: February 2023 Competition||$7,000 to $75,000 for 1-2 years.||Insight Development Grants support research in its initial stages. The grants enable the development of new research questions, as well as experimentation with new methods, theoretical approaches and/or ideas. Funding is provided for short-term research development projects of up to two years that are proposed by individuals or teams.||February 2, 2023.|
|Tri-Agency||SSHRC Partnership Grants 2023 Competition||Stage 1: Up to $20,000. |
Stage 2: Up to $2,500,000 for 4-7 years.
|Partnership Grants are intended for large teams working in formal collaboration between postsecondary institutions and/or organizations from the public, private and/or not-for-profit sectors, to advance research, research training and/or knowledge mobilization in any of the disciplines eligible for funding at SSHRC.||Stage 1: February 10, 2023.
Stage 2 (by invitation only): TBA.
|Tri-Agency||CIHR Team Grant: CIHR-JDRF Type 1 Diabetes Screening Research Consortium||$3,000,000 per year for up to 4 years.||The goal of the CIHR-JDRF Type 1 Diabetes Screening Research Consortium is to develop a single nationally coordinated research Consortium to explore key research questions pertaining to the feasibility and acceptability of a general population T1D screening program in Canada, building on experiences from other countries.||Registration: February 15, 2023.
Application: March 14, 2023.
|Tri-Agency||CIHR Team Grant: Intervention Trial in Inflammation for Chronic Conditions||Development Grant: Up to $20,000 per grant; Full Application: Up to $500,000 per year for up to 4 years for Research Team Grants; Up to $145,000 per year for up to 4 years for the KM Hub.||This will support intervention trials in humans with clinical impact on inflammation in chronic conditions and knowledge mobilization. The overall vision of this funding opportunity is to improve the health outcomes of people living with, or at risk of developing, chronic conditions by advancing the repurposing, development, and optimization of innovative interventions. Interventions are to target biological (e.g., genetic, epigenetic), environmental (e.g., exposure to chemical products, air pollution), social (e.g., socioeconomic status, education) and behavioral (e.g., tobacco or cannabis smoking, vaping, diet) triggers of shared pathways of inflammation across two or more chronic conditions. This funding opportunity is composed of two main types of grants: Research Team Grants; Knowledge Mobilization Hub (KM Hub). Note: Those interested in applying for a Research Team Grant and the KM Hub will need to submit two full applications. Applying for the KM Hub is optional and will be reviewed with evaluation criteria that are independent from the Research Team Grants.||Letter of Intent: March 2, 2023.
Full Application (by invitation): March 6, 2024.
|Tri-Agency||CIHR Other: IYS-Net Phase 1: Building Learning Health System Networks||Stream 1 Network Grants: Up to $291,000 per year for up to 5 years.||The goal of IYS-Net is to create a pan-Canadian network of Learning Health System (LHS) networks (a 'network of networks'). Through these LHSs, IYS-Net aims to improve equitable and inclusive access to evidence-informed services for mental health and substance use health and improve equitable outcomes for all youth. IYS Networks are expected to enable LHSs through various processes: (i) collecting and synthesizing data from real-world practice ('practice to data'), (ii) using that data to answer questions and generate new and useful knowledge ('data to knowledge'), and (iii) applying that knowledge to improve care to equitably meet the needs of youth, caregivers/families and communities served ('knowledge to practice'), which includes knowledge mobilization and implementation science||Registration: April 4, 2023.
Application: May 17, 2023.
|Tri-Agency||NSERC Alliance Grants||$20,000 to $1 million per year for 1-5 years||Support university researchers to collaborate with partner organizations, which can be from the private, public or not-for-profit sectors.|
NOTE: All NSERC grant applications must be submitted through the University of Toronto Research Services Office.
|Tri-Agency||NSERC Alliance International||Catalyst Grants: $25,000 for 1 year.|
Collaboration Grants: Up to $100,000 per year for up to 3 years.
|These are for Canadian university researchers working in the natural sciences and engineering in partnership with international collaborators from the academic sector. The overall objectives are to: 1) allow Canadian researchers to initiate the development of international collaborations; and 2) provide support for Canadian researchers participating in international collaborative projects of global importance and benefit to Canada. The applicant and any Canadian co-applicants must have an active NSERC peer-reviewed grant, as primary applicant, at the time of application. |
NOTE: All NSERC grant applications must be submitted through the University of Toronto Research Services Office.
|Other Canadian||Alberta Gambling Research Institute (AGRI): Various Opportunities||Leveraging Grants: Up to $80,000.|
Team Development Grants: Up to $10,000 for up to 18 months.
Small Grants: T Up to $10,000 for up to 1 year.
|Leveraging Grants: To enable researchers, with non-AGRI funding to augment projects with a gambling-related component. Value: Up to $80,000. Deadline: Rolling call.|
Team Development Grants: To support the development of multi/interdisciplinary teams of academic researchers, among Partner Universities, nationally, internationally, and other stakeholders in order to establish research programs Value: Up to $10,000 for up to 18 months. Deadline: Rolling call.
Small Grants: To support small developmental initiatives typically intended to lead to major grant applications. Value: Up to $10,000 for up to 1 year. Deadlines: October 1st and May 1st each year.
NOTE: For AGRI grants, the applicant must be one of the principal investigators and have grant-holding status at the University of Alberta, Calgary, or Lethbridge. Research collaborators may come from other institutions.
|Leveraging Grants: Rolling call.
Team Development Grants: Rolling call.
Small Grants: October 1st and May 1st each year.
|Other Canadian||Canadian Blood Services (CBS) Kenneth J. Fyke Award||$100,000 for 1 year.||This supports supports health services and policy research in order to promote the development of evidence-based Canadian practices and policies in blood transfusion, blood stem cell transplantation, and organ and tissue donation and transplantation for the benefit of Canadian patients.||November 30, 2022.|
|Other Canadian||Data Sciences Institute (DSI): Various Opportunities||Please see individual funding opportunity description.||Critical Investigation of Data Science Grant: This provides seed funding for scholars to engage in critical investigations of data science. Projects can vary in scope from analysis of specific data science projects and approaches to the articulation of potential harms in data science writ large. A variety of methodological and epistemological approaches are welcome, including critical analysis, social inquiry, phenomenology, qualitative investigations of lived experiences, content analysis, rhetorical approaches, and/or the creation or evaluation of models, algorithms, and other data science methodologies. Value: Up to $10,000 for up to 12 months. |
Banting-CANSSI Discovery Award in Biostatistics: These support early-career investigators who are within the first three years of their academic appointment at a Canadian university or at one of their affiliated research institutes. Applicants are required to propose innovative statistical or computational methodology research and demonstrate interdisciplinary collaboration with a health scientist on a project that has the strong potential to advance health, health equity, and/or patient outcomes. Important Note: Departments, or Single Unit Divisions, may only select one candidate for this competition. Value: Up to $30,000 for 1 year.
|Banting-CANSSI Discovery Award in Biostatistics: Notice of Intent: December 1, 2022; Full Application (by invitation): January 24, 2023.|
|Other Canadian||U of T Data Sciences Institute (DSI) Banting-Data Sciences Institute Discovery Award in Data Science||Up to $30,000 for 1 year.||This is for early-career investigators within the first 3 years of the date of their first academic appointment as of the application deadline date of January 24, 2023. Applicants must be budgetarily appointed at U of T or at a DSI external research institute (Unity Health is a research institute member) and members of the DSI. Applicants should propose new, innovative statistical or computational methodology, or propose to implement existing methods in novel ways, to address a health or biomedical research question.||Notice of Intent: December 1, 2022.
Application: January 24, 2023.
|Other Canadian||UofT McLaughlin Centre Accelerator Grants in Genomic Medicine 2023: "Genome Networks and Data Science in Health and Disease"||$100,000 for 1 year.||Priority will be given to applications demonstrating promise for near-term deliverables, potential to seed larger grants, and those involving two or more institutions from the University of Toronto Faculties (and their Departments and Institutes) and the hospitals/research institutes fully affiliated with the University of Toronto (TAHSN). A requirement is that the McLaughlin Centre investment be equally leveraged with other funds necessary for the project. For enquiries or direct submissions contact:|
Hin Lee PhD, Program Manager, McLaughlin Centre (email@example.com; 416-813-7654 ext. 309335)
|Letter of Intent: December 2, 2022.
Application (by invitation): March 3, 2023.
|Other Canadian||TRANSFORM HF: Various Opportunities||Seed Grant Funding Competition: $70,000.|
ECHO Discovery: Free virtual program running from January-June 2023.
|Seed Grant Funding Competition: Projects must align with one, or a combination, of the following research themes: 1. Equity, diversity, accessibility, and inclusion in heart failure; 2. Data science innovation in heart failure prevention, treatment, or care; 3. Digital health (including virtual health, point-of-care testing, implantables, sensors, wearables, and apps) and heart failure. Teams that expand the TRANSFORM HF network outside the U of T and TASHN hospitals will be prioritized.|
ECHO Discovery: For fourth-year undergraduate students and graduate students enrolled in a Canadian university, and post-doctoral and clinical fellows affiliated with the TAHSN who are interested in exploring research translation and entrepreneurship within the cardiovascular health sector but have limited understanding of how to proceed.
|Seed Grant Funding Competition: December 5, 2022.
ECHO Discovery: November 18, 2022.
|Other Canadian||Public Health Agency of Canada (PHAC): Invitation to submit a letter of intent: Enhanced Surveillance for Chronic Disease Program (ESCDP) 2022||Up to $1,000,00 for 1 to 3 years.||The ESCDP's objective is to enhance capacity for public health, chronic disease and injury surveillance activities. For this funding program, surveillance means the tracking of health events and determinants through the: Ongoing collection of data; Integration, analysis and interpretation of data; Dissemination of information to those who can benefit by using the evidence. The current solicitation aims is to build surveillance capacity and fill data gaps in three priority areas: Substance related harms, including opioids; Mental health and mental illness; and, Longer term impacts of COVID-19 including post-COVID condition and chronic disease.||Letter of Intent: December 8, 2022.
Full Application (by invitation): TBA.
|Other Canadian||Canadian Blood Services: BloodTechNet Award||Up to $50,000 for up to 1 year.||This supports the development of innovative educational projects that network the Transfusion, Cellular Therapy and Transplantation communities in Canada. These projects deliver educational tools and resources that support the development of skills, knowledge and expertise of the health professionals in this network. The BloodTechNet Award Program is targeted towards medical lab technologists, nurses and physicians.||December 15, 2022.|
|Other Canadian||INOVAIT Pilot Fund - Call for Applications - Image-Guided Therapy and AI||Between $100,000 and $125,000 for 9-15 months. INOVAIT contributes up to one-third (33.33%) of total eligible supported costs in the form of reimbursement funding.||INOVAIT provides Canada's image-guided therapy (IGT) industry and academic institutions with targeted non-dilutive funding for commercialization-focused R&D projects involving the integration of artificial intelligence (AI) into IGT technologies.This call provides pilot funding to support industrial research, including activities related to the discovery of new knowledge that aim to support the development of new technology-driven products or services and large-scale technology demonstration, including the advancement and development of new technologies into product-specific applications. Each project must involve two to four Canadian collaborators and must actively involve at least one Canadian small and medium enterprise (SME).||December 20, 2022.|
|Other Canadian||Public Health Agency of Canada (PHAC): Healthy Canadians and Communities Fund||Between $200,000 and $3,000,000 for 2 to 4 years.||This probram aims to prevent chronic disease by funding interventions in the area of primary prevention. This means projects need to address risk factors, including tobacco use, unhealthy eating, and physical inactivity. The objectives are to invest in interventions that address health inequalities, encourage multi-sectoral participation in chronic disease prevention, uncover new ways to address the risk factors for chronic disease. PHAC is presently only accepting applications for the implement phase.|
The implement phase is about project delivery with partners and evaluation of your intervention. The project must focus on one or more of the program's priority population groups.
|Screening Form: December 21, 2022.
Full Proposal (by invitation): TBD
|Other Canadian||Canadian Anesthesiologists' Society (CAS) - Various Opportunities||Please see individual funding opportunity description.||This provides support to researchers in anesthesia who are CAS members.|
Career Scientist Award: Provides partial salary support over two years to a qualified new investigator to fund a minimum of two days per week of protected research time. The award requires availability of $60,000 in matching funds from the successful applicant's university or faculty. Applicants must be Active members of the CAS and have a minimum one year of formal research training, with this training having been completed within ten years of the application deadline. Value: $60,000 from CAS over 2 years.
New Investigator Operating Grants: for applicants who have commenced independent practice/received their first faculty appointment within five years of the application deadline, or have undertaken significant research training (i.e., obtaining a Master's degree or PhD) within the past three years. Value: up to $20,000 or up to $30,000 over 2 years
Open Operating Grants: Applicants may be at any stage of their career development but must hold a faculty appointment at a Canadian medical school. Value: Up to $20,000 or up $30,000 over 2 years.
Section Operating Grants: Individuals are eligible to apply for Section Grants if they are a current member of the Section offering the award and the proposed research is directly related to the Section's goals and objectives. Value: Up to $10,000 or up to $20,000.
|December 22, 2022.|
|Other Canadian||Kidney Foundation of Canada (KFOC): Various Opportunities||Please see individual funding opportunity description.||The KFOC national research fund encourages research that advances current knowledge pertaining to the kidney, diseases of the kidney, organ donation and transplantation.|
- Kidney Research Scientist Core Education and National Training (KRESCENT) Program New Investigator Award: For individuals who have clearly demonstrated excellence during their pre-doctoral and post-doctoral training in kidney disease. Value: $65,000 or $70,000 per year of salary support for up to 3 years.
- Allied Health Kidney Grants: To encourage allied health professionals to pursue research relevant to the areas of nephrology and organ donation, including clinical, health services, social, cultural, environmental and population health research. To be eligible for this grant the principal applicant must be an allied health professional. Value: Up to $50,000.
|Kidney Research Scientist Core Education and National Training (KRESCENT) Program New Investigator Award: January 11, 2023.
Allied Health Kidney Grants: March 8, 2023.
|Other Canadian||Canadian Paediatric Society Neonatal Resuscitation Programme (NRP): Various Opportunities||Please see individual funding opportunity description.||Submitted studies may include basic science, clinical, epidemiological or educational research pertaining to the broad area of neonatal resuscitation, however submissions in the following research priorities areas are highly encouraged: Post-resuscitation neonatal stabilization (The First Hour); Quality assurance and neonatal resuscitation (e.g. team performance, medical error, consistency in care); Resuscitation physiology (e.g. CPAP, novel techniques); Resuscitation education (simulation and debriefing).|
Research Grant: Applicants may include established investigators (> 10 years since primary appointment). Value: Up to $25,000.
Emerging Investigator Award: Applicants must have completed their primary professional degree/diploma within the past five (5) years. Value: Up to $5,000.
|January 15, 2023.|
|Other Canadian||Canadian Space Agency (CSA) Announcement of Opportunity (AO): Health & Life Sciences Data and Sample Mining (DM) or Research Models (RM)||Please see individual funding opportunity description.||The intent is to conduct science investigations that will lead to a better understanding of human spaceflight risks while contributing to improve remote medicine and health benefits here on Earth.|
Topic 1 (Data and Sample mining (DM)): Solicits proposals for scientific analysis, using databases or samples derived from existing collections to improve the understanding of the risks of spaceflight or for initial validation of new countermeasures. Value: Up to $70,000 for a up to 1 year.
Topic 2 (Research Model (RM)): Research to be funded will be to use non-human subject research models (for example animals, organoids, cell culture, or microorganisms) to investigate space-related health risks and identify sex differences, if applicable. Value: Up to $150,000 for up to 2 years.
|January 16, 2023.|
|Other Canadian||Canadian Allergy, Asthma, and Immunology Foundation (CAAIF): Allergic Airways Disease Innovation Grant||Up to $85,000 for 1 year.||The objective of the Allergic Airways Disease Innovation Grant is to fund innovative research of a "high-risk, high-reward" nature that will have impact on the prevention or treatment of allergic airways disease. The Project must fall within CAAIF's mission and the mandate of the CIHR Institute of Circulatory and Respiratory Health.||January 16, 2023.|
|Other Canadian||AMS Healthcare: Funding in Compassion and Artifical Intelligence (AI)||Please see individual funding opportunity description.||Fellowship in Compassion and AI: If you are early to mid-career, have a PhD or a Master's degree, and your work helps answer the question, "How can digital technology and artificial intelligence change the healthcare we provide?" you can apply. Value: $75,000 for 12 months. |
Grants: These support projects that will generate new knowledge and evidence to advance the education/training of undergraduate, graduate, and practicing healthcare professionals, and clinical health systems, and related field researchers on compassionate care and AI. Value: $20,000 for 12 months.
|Fellowship in Compassion and AI: Letter of Intent: January 20, 2023; Full Application (by invitation): April 12, 2023.
Grants: February 22, 2023.
|Other Canadian||Public Health Agency of Canada (PHAC): Type 2 Diabetes Prevention Challenge||Stage 1 (Proposed Concept): $35,000; Stage 2 (Concept Development): $600,000; Stage 3 (Implementation and Evidence Generation): $1,250,000.||This is to develop and implement community co-designed approaches that address the barriers and determinants of health that lead to having an increased risk for Type 2 Diabetes (T2D). It seeks innovative approaches to T2D prevention for people before they require entry into the medical system, which use a combination of community strengths and resources from inter-sectoral partnerships to overcome the barriers to T2D diabetes prevention for communities in Canada, particularly those that address the determinants of health in communities with an already higher risk.||Stage 1: March 1, 2023.; Stage 2 (by invitation): Fall 2023; Stage 3 (by invitation): Winter 2026.|
|Other Canadian||Cystic Fibrosis Canada (CFC): Various Opportunities||Seed Grants: Up to $50,000 for 1 year.||Seed Grants: Small, short-term grants focused on a new idea without other funding and without preliminary data. Not to be used to support an existing project that was not successful through the Basic and Clinical Research Grants competition.||Seed Grants: Anticipated April 1, 2023.|
|Other Canadian||University of Toronto Institutional Strategic Initiatives (ISI)||From $50,000-$300,000 per year for up to 3 years.||ISI awards are intended to establish research capacity in high-priority areas, with the goal of realizing transformational impacts on issues of societal importance. Proposed investigator-initiated initiatives must meet the following key criteria: 1) Address a significant challenge and associated research questions that requires an interdisciplinary approach; 2) Matching funds secured from three or more Academic Divisions; 3) Path to sustainability demonstrated by a clear opportunity for external funding.||Ongoing|
|Other Canadian||Collaboration Opportunities: National Research Council Canada (NRC) Challenge Programs||--||The NRC offers potential opportunities for collaboration in the following areas:|
- Aging in Place
- Artificial Intelligence for Design
- Disruptive Technology Solutions for Cell and Gene Therapy
- High-throughput and Secure Networks
- Pandemic Response
Potential collaborators can register their interest to work with NRC on the Challenge Programs website.
|Other Canadian||Government of Canada: CanExport for Innovators||Maximum of $75,000||Specifically designed to promote and enhance Canada's international innovation efforts. Eligible expenses may include international and local travel, accommodation, meals, meeting costs, legal fees to support formalized partnerships, and other costs related to international collaboration.|
Applications must be submitted at least 8 WEEKS prior to the anticipated start date of the activities.
|Other Canadian||Weston Brain Institute: Early Phase Clinical Trials: Canada||Up to $1,500,000 per project for up to 4 years||Funding for clinical trials and/or clinical trial sub-studies with excellent preliminary data.||Rolling deadline
|Other Canadian||Physicians' Services Incorporated (PSI) Foundation: Health Research Grant & New Investigator Grant||Health Research Grant: Up to $250,000 for 3 years.|
New Investigator Grant: Up to $300,000 for 3 years.
|Areas of Support: clinical research, medical education research, health systems research. Applicant must be a College of Physicians and Surgeons of Ontario licensed MD. New Investigators must be within five years of their first academic appointment.||Rolling deadline|
|Other Canadian||Telus Funds||Various||For entertaining and engaging web series with the potential to positively impact families and friends providing care for loved ones struggling with a health condition.||Various
|Other Canadian||Ontario Centre of Innovation (OCI) Voucher for Innovation and Productivity (VIP) Program||Minimum of $20,000 up to a maximum of $150,000 per year towards the direct costs of research (Industry Partner contribution has to be minimum of 1:1 cash match to the OCE contribution, where at least 50% must be spent at the post-secondary institution.)||This program helps companies develop, implement and commercialize technical innovations by supporting partnerships between Ontario's industry and publicly funded post-secondary institutions and research hospitals. VIP projects are intended to generate economic benefit for companies in Ontario (including job creation/retention, new revenue generation, investment attraction, cost savings, value chain development), in the short-to-medium term (e.g. within three years of project completion).|
If you are interested, please contact Samar Saneinejad (Samar.Saneinejad@unityhealth.to).
|International||Pre-Announcement: US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY22 Toxic Exposures Research Program (TERP)||Investigator-Initiated Research Award: Up to USD $500,000 for up to 3 years.|
Translational Research Award: Up to USD $800,000 for up to 3 years; Up to USD $1.6M for up to 3 years with Partnership Option.
Clinical Trial Award: Up to USD $1.5M for up to 4 years; Up to USD $2.5M for up to 4 years with Partnership Option.
|The CDMRP has pre-announced the following FY 2022 opportunities. Please see details of these at the TERP link.|
Investigator-Initiated Research Award: Supports studies that will make an important contribution toward research and/or patient care for a disease or condition related to toxic exposures.
Translational Research Award: Supports hypothesis-driven, high impact translational research that will accelerate the movement of promising ideas into clinical applications, including healthcare products, interventions, technologies, and/or clinical practice guidelines.
Clinical Trial Award: Proposed projects may range from small proof-of-concept clinical trials (e.g., pilot, first-in-human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials through large-scale trials to determine efficacy in relevant patient populations.
|International||US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY22 Breast Cancer Research Program (BCRP) Clinical Research Extension Award (CREA)||Up to USD $5 million or up to USD $6 million with the Partnering PI Option for up to 4 years.||This supports research that extends the data collection, follow-up, and analysis of breast cancer clinical research studies. The intent is to increase the clinically relevant impact of breast cancer patient participation in clinical research by addressing the knowledge lost due to limited or early termination of patient follow-up and sample collection and analysis. Research proposed under this mechanism may entail a deeper molecular analysis of clinical samples, initiation of new correlative studies, biomarker validation, or continuing clinical follow-up of patients currently/previously enrolled in an open/ongoing or completed clinical trial.||Pre-Application: November 29, 2022.
Application: December 13, 2022.
|International||Bayer Hemophilia Awards Program (BHAP): Various Opportunities||Please see individual funding opportunity description.||Clinical Research Award: Provides funds to undertake a clinical research project in the bleeding disorders field. Value: Up to USD $75,000 for 1 year.|
Basic Research Award: Provides funds to undertake a basic research project in the bleeding disorders field. Value: Up to USD $75,000 for 1 year.
Patient Engagement Award: Provides funds to support efforts in the field of patient engagement, education and advocacy within hemophilia. It recognizes the essential role of nurses, allied healthcare professionals and caregivers in the care of patients with hemophilia. Value: Up to USD $25,000 for 1 year.
|Letter of Intent: November 30, 2022.
Full Proposal (by invitation): February 2023.
|International||Pre-Announcement: Eighth Global Alliance for Chronic Diseases (GACD) Call: Non-Communicable Disease (NCD) Prevention in Cities||--||This supports implementation research that leads to improved understanding of how specific interventions that reduce the risk of NCD onset or progression can be better adapted to different city environments and/or scaled within and across cities, taking into account unique local social, political, economic, and cultural contexts. Projects will occur in disadvantaged populations in low- and middle-income countries and/or in high income countries.||Call Launch: November 30, 2022.
Letter of Intent: March 31, 2023.
Full Application: May 31, 2023.
|International||American Association for Thoracic Surgery (AATS) Foundation: Various Opportunities||Please see individual funding opportunity description.||Equity Award: This is for early to mid-career women and faculty underrepresented in medicine to develop the foundations for successful careers in academic cardiothoracic surgery. Early to mid-career thoracic surgeon is defined as instructor and assistant professor level, between 3 and 8 years of initial faculty appointment, and have an academic medical centre faculty appointment. Value: Up to USD $50,000 per year for up to 3 years.|
Research Scholarship: This program is designed as an early-career development award for young surgical scientists. Applications for the scholarship must be submitted during the candidate's first two years in an academic position. Candidates must have completed their cardiothoracic residency within 3 years of application. Value: USD $80,000 per year for 2 years.
|December 1, 2022.|
|International||Sigma Foundation for Nursing: Nursing Research and Program Grants||Sigma/American Association of Critical-Care Nursing Grant: Up to USD $10,000. Deadline: November 1, 2022.|
Small Grants: Up to USD $5,000 for up to 1 year.
Alpha Eta Collaborative Research Grant: Up to USD $5,000 for up to 1 year.
Canadian Nurses Foundation Collaborative Grant: Up to USD $5,000 for up to 1 year.
Council for the Advancement of Nursing Science: Up to USD $5,000.
Rosemary Berkel Crisp Research Award: Up to USD $5,000 for up to 1 year.
|Sigma/American Association of Critical-Care Nursing Grant: To encourage qualified nurses to contribute to the advancement of nursing through critical care nursing practice research.|
Small Grants: Projects that focus on marginalized populations are strongly encouraged and will be given preference, other qualifications being equal.
Alpha Eta Collaborative Research Grant: Available to Chi Omicron At-Large Chapter, Chi Xi At-Large Chapter, and/or Tau Lambda At-Large Chapter members for a new research project in Africa.
Canadian Nurses Foundation Collaborative Grant: Supports research that advances the practice of nursing with an emphasis on nursing care issues.
Council for the Advancement of Nursing Science: Proposals for clinical, educational or historical research, including plans for broadly disseminating the research findings, may be submitted for the grant.
Rosemary Berkel Crisp Research Award: Supports nursing research in the critical areas of women's health, oncology, and pediatrics.
|Sigma/American Association of Critical-Care Nursing Grant: December 1, 2022.|
|International||National Blood Foundation (NBF) Scientific Research Grants Program||Maximum USD $75,000 for 1 year or 2 years.||NBF awards grants for investigator-initiated original research in all aspects of blood banking, transfusion medicine, biotherapies and patient blood management. Priority in awarding grants will be given to innovative, new projects. Grants are awarded to early-stage investigators. An early-stage investigator is a new investigator who has completed a terminal research degree or medical residency - whichever date is later - within 10 years of the grant application deadline and has not yet been awarded a substantial research grant.||December 1, 2022.|
|International||Myocarditis Foundation (MF) Research Grants||USD $50,000 for 1 year.||The MF sponsors myocarditis research grants dedicated to diagnosis, treatment and an eventual cure. These are intended to offer seed funding to support the early stages of long-term research, from the investigation of an initial hypothesis to the collection of preliminary data. Applicants must apply within 10 years after earning an MD, PhD or equivalent degree.||December 1, 2022.|
|International||American Laryngological Association (ALA): ALA/ALVRE Research Grant||USD $10,000 for 12 months plus $1,000 in travel expenses to the ALA annual meeting.||This is to support basic, translational, or clinical research projects in laryngology (voice, airway, swallowing), outcomes, and related subjects, and should lead to furthering the fields of laryngology or neurolaryngology. Candidates for this award should be otolaryngologists who have completed or are presently in their training at an ACGME accredited program in otolaryngology - head and neck surgery.||Letter of Intent: December 1, 2022.
Application: January 16, 2023.
|International||Google Research Scholar Program||USD $60,000.||This supports early-career professors who are pursuing research in fields relevant to Google. Applicants must have received their PhD within seven years of submission (e.g. applicant in 2022 must have received PhD in 2015 or later). Applicant must be full-time faculty at a degree-granting institution (apply through U of T).||December 1, 2022.|
|International||Cancer Research Institute (CRI): Various Opportunities||Clinic and Laboratory Integration Program Grants: Up to USD $100,000 per year for up to 2 years. |
Lloyd J. Old STAR Program: Up to USD $250,000 per year for up to 5 years.
|Clinic and Laboratory Integration Program Grants: Provides funding for qualified scientists who are working to explore clinically relevant questions aimed at improving the effectiveness of cancer immunotherapies. The grant will support pre-clinical and translational research, which will provide information that can be directly applied to optimizing cancer immunotherapy in the clinic. |
Lloyd J. Old STAR Program: To support world-class academic investigators who have made notable contributions to immunotherapy and have the greatest potential to propel the field forward. It is expected that their discoveries in basic or translational research will ultimately influence the development of new immune-based therapies that will be effective for more cancer patients.
|Clinic and Laboratory Integration Program Grants: Letter of Intent: December 1, 2022; Application (by invitation): March 1, 2023.
Lloyd J. Old STAR Program: January 15, 2023.
|International||Paralyzed Veterans of America (PVA) Education Foundation Grants||Ranges between up to USD $10,000 to USD $50,000, depending on the topic category. All grants are for 12 months.||This funds educational projects that benefit and serve individuals with SCI/D, their families and caregivers. There are six topic categories for funding consideration, which are: Consumer, Caregiver, and Community Education; Professional Development and Education; Research Utilization and Dissemination; Assistive Technology; Consumer Guides; and Conferences and Symposia.||December 2, 2022.|
|International||Burroughs Wellcome Fund (BWF): Next Gen Pregnancy Initiative||Up to USD $125,000 per year for up to 4 years.||The initiative is designed to stimulate both creative individual scientists and multi-investigator teams to approach healthy and adverse pregnancy outcomes using creative basic and translation science methods. Proposals should address the biomedical causes and molecular mechanisms underlying adverse pregnancies and their outcomes including but not limited to peri-implantational events, placentation, fetal determinants, fetal-maternal immune responses, biological basis for racial-ethnic disparities, mechanisms relating preterm birth to other adverse pregnancy outcomes, biology of normal labor, genomics, evolutionary influences, maternal complications and other approaches. Proposals seeking to identify biomarkers predicting preterm birth are welcome. The formation of new connections between reproductive scientists and investigators who are involved in other areas is particularly encouraged.||December 2, 2022.|
|International||American College of Gastroenterology (ACG): Various Opportunities||Please see individual funding opportunity description.||The ACG seeks original, patient-oriented research in clinical gastroenterology and hepatology, defined as: 1) Research conducted with human subjects; 2) Research on new diagnostic and therapeutic intervention; 3) Research on material of human origin such as tissues and specimens; 4) Research that is translational in nature; i.e., has direct applicability to clinical care. |
Junior Faculty Development Award: For junior investigators <7 years out of fellowship working toward independent careers in clinical research related to gastroenterology or hepatology who hold full-time faculty positions and have 50% protected time. To apply, you must be an ACG Member. Value: USD $450,000 for 3 years.
Established Investigator Bridge Funding Award: Provides support for established investigators with bridge funding for clinical research related to gasteroenterology or hepatology, who have evidence of recent concluded or newly anticipated federal funding. To apply, you must be an ACG Member. Value: USD $300,000 for 2 years.
Health Equity Research Award: Supports actionable science that will translate to reducing health and/or healthcare disparities for faculty or practicing gastroenterologists hepatologists in community practice. To apply, you must be an ACG Member. Value: Up to USD $75,000 for up to 2 years.
Clinical Research Award: Supports innovative patient-oriented research with direct applicability to clinical care. Preliminary data is required. at least one of the investigators must be an ACG Member or Trainee Member at the time of submission. Value: Up to USD $50,000 for up to 1 year.
Clinical Research Award Pilot Projects: To encourage clinical research among trainees and junior faculty. Previous work or preliminary data is not required. At least one of the investigators must be an ACG Member or Trainee Member at the time of submission. Value: Up to USD $15,000 for 1 year.
ACG/ASGE Epidemiologic Research Award in Gastrointestinal Endoscopy: For projects involving the use and outcomes of gastrointestinal (GI) endoscopy using the GI Quality Improvement Consortium (GIQuIC). Must be an ACG or ASGE Member at the time of submission.
|December 5, 2022.
ACG/ASGE Epidemiologic Research Award in Gastrointestinal Endoscopy:December 9, 2022.
|International||American Association for the Study of Liver Diseases (AASLD) - Various Opportunities||Range from USD $20,000 - $100,000 per year for up to 3 years. Please see description for details.||Pinnacle Research Award in Liver Diseases: This is a basic science award that is intended to develop the potential of outstanding, young scientists and encourage research in liver physiology and disease. Applicants must be within the first six years of their first faculty appointment at the start of the award. Value: USD $300,000 over 3 years ($100,000 per year).|
Clinical, Translational and Outcomes Research Award: This award is intended to foster career development for individuals performing clinical research, translational research, or outcomes research in a liver-related area and who have shown commitment to excellence at an early stage of their research study. Applications in health disparities-related research are encouraged. Applicants must be within the first six years of their first faculty appointment at the start of the award. Value: USD $200,000 over 2 years ($100,000 per year). NOTE: Up to two applications per distinct department will now be accepted per single sponsoring institution.
Pilot Research Award in Liver Diseases: This supports highly innovative research ideas that have a clear potential to produce high-impact results, but that have little or no preliminary data. Applicants must be faculty 3 years post appointment to at or below the Associate Professor Level. Value: USD $50,000 for 1 year.
Autoimmune Liver Diseases Pilot Research Award: This provides supplementary funding during the pilot phase of basic, translational or clinical research projects in autoimmune liver disease (e.g. autoimmune hepatitis, primary sclerosing cholangitis, primary biliary cholangitis) in preparation for future grant applications by the recipient. Applicants must be within the first six years of their first faculty appointment at the start of the award. Value: USD $20,000 for 1 year.
Gupta Family Pilot Award in PSC Research: This award supports new, highly innovative PSC research ideas that focus on questions pertaining to the pathogenesis, diagnosis, and/or management of PSC in children and/or adults. Responsive projects will address highly innovative research ideas that have a clear potential to produce high-impact results, but that have little or no preliminary data to successfully compete for funding from other sources. Applicants must be at or below the rank of Associate Professor. Value: USD $50,000 for 1 year.
|Pinnacle Research Award in Liver Diseases: December 5, 2022.
Clinical, Translational and Outcomes Research Award: December 5, 2022.
Pilot Research Award in Liver Diseases: December 5, 2022.
Autoimmune Liver Diseases Pilot Research Award: Deadline: December 5, 2022.
Gupta Family Pilot Award in PSC Research: December 5, 2022.
|International||Pfizer Global Medical Grants (GMG) Request for Proposals (RFP): Engaging the Patient Community in Research and Publications||Up to USD $20,000.||Through this RFP, Pfizer intends to provide grants to strengthen the capabilities of the patient community by providing mentorship and training on how to conduct patient-partnered research with the goal to facilitate increased opportunities for collaboration between patients and academic research communities.||December 8, 2022.|
|International||Cystic Fibrosis Foundation (CFF): Various Opportunities||Please see individual funding opportunity description.||Pilot and Feasibility Awards: Support basic science research studies focused on developing and testing new hypotheses in areas relevant to cystic fibrosis. Value: Up to USD $50,000 per year for up to 2 years.|
Path to a Cure (PTAC) Program: Projects supported through the PTAC initiative should focus on foundational concepts, strategies, novel tools and methods, and/or technologies that have the potential to inform or ultimately translate into novel therapies to restore CFTR protein function or fix/replace the defective CFTR gene. Value: PTAC Research Grant: Up to USD $150,000 per year for up to 2 years; PTAC Pilot and Feasibility Award: Up to USD $50,000 per year for up to 2 years.
|December 8, 2022.|
|International||American Society for Gastrointestinal Endoscopy (ASGE): Various Opportunities||Please see individual funding opportunity description.||ASGE Research Grant: For projects in basic, translational and clinical research with a relationship to gastrointestinal endoscopy. Applicant is required to be an ASGE member at the time of application, be an MD (or have equivalent degree), and be currently practicing in North America. Value: Up to USD $75,000 for up to 2 years.|
ACG/ASGE Epidemiologic Research Award in Gastrointestinal Endoscopy: Provides support for projects involving studies on the use and outcomes of gastrointestinal (GI) endoscopy using the GI Quality Improvement Consortium (GIQuIC). Applicant is required to be an ACG or ASGE member at the time of application, and be a physician or clinical researcher (MD, DO, or PhD). Value: Up to USD $50,000 for 1 or 2 years.
ASGE Diversity and Inclusion Research Award: Supports studies that advance the field of gastroenterology research and focus on minority health as well as healthcare disparities as it relates to GI disease. Applicant is required to be an ASGE member at the time of application, be an MD (or have equivalent degree), and be currently practicing in North America. Value: Up to USD $50,000 for up to 2 years.
|December 9, 2022.|
|International||ResMed Foundation: Various Opportunities||Physician and Public Awareness Proposals: USD $10,000. ||Physician and Public Awareness Proposals: To further the awareness and knowledge of the inherent dangers of untreated SDB, its symptoms, diagnosis and treatment with sleep specialists, primary care physicians, educators and the general public.||Physician and Public Awareness Proposals: December 15, 2022.|
|International||American College of Surgeons (ACS): Faculty Research Fellowships||USD $40,000 per year for 2 years.||These are to assist a surgeon in the establishment of their research program under mentorship with the goal of transitioning to becoming an independent investigator. Applicants should have demonstrated their potential to work as independent investigators. Open to Fellows or Associate Fellows of the College who have: (1) completed the chief residency year or accredited fellowship training within the preceding five years, not including time off for maternity leave, military deployment, or medical leave; and (2) received a full-time faculty appointment in a department of surgery or a surgical specialty at a medical school.|
- Franklin H. Martin, MD, FACS, Faculty Research Fellowship of the ACS
- C. James Carrico, MD, FACS, Faculty Research Fellowship for the Study of Trauma and Critical Care
|December 15, 2022.|
|International||Cystic Fibrosis Foundation (CFF): Various Opportunities||Please see individual funding opportunity description.||CFF/NIH R01-Unfunded Award: This supports excellent cystic fibrosis-related research projects that have been approved by the National Institutes of Health (or governmental funding agencies in other countries) but cannot be supported by available funds. Value: Up to USD $125,000 per year for up to 2 years. |
Path to a Cure - Pioneer Award: For ambitious basic research projects aiming to utilize cutting-edge techniques and strategies that have the potential to discover new genetic-based therapies for cystic fibrosis.
|CFF/NIH R01-Unfunded Award: December 15, 2022.
Path to a Cure - Pioneer Award: Rolling.
|International||Gates Foundation Global Grand Challenges: Various Opportunities||Please see individual funding opportunity description.||Strengthening Modeling and Analytics Capacity and Ecosystem for Women's Health: This seeks innovative approaches to modeling of women's health issues or of broader health topics that incorporate a gender lens. Gates foundation seeks collaborative proposals led by investigators in low-income and middle-income countries (LMICs) - particularly applications from women-led organizations and applications involving projects led by women. Value: Up to USD $500,000 for 1 to 3 years.|
Pathogen Genomic Surveillance and Immunology in Asia: Seeks projects from investigators in South and Southeast Asia that address one or both of the following two goals: 1) Asia Pathogen Genomics Initiative (Asia PGI): Design and pilot a genomic surveillance program for a priority pathogen (other than SARS-CoV-2, where proposals are invited from country National Public Health Institutions (NPHIs) or public laboratories with links to the public health system; 2) Global Immunology and Immune Sequencing for Epidemic Response (GIISER) - Asia: Develop capacity for immune characterization of SARS-CoV-2 variants to inform Epidemic Response, which seeks proposals from NPHIs or their academic partners to increase the in-country capacity for rapid immunological evaluation of SARS-CoV-2 variants in South and Southeast Asia. Value: Up to USD $300,000 per year for up to 2 years.
|December 16, 2022.|
|International||American Academy of Otolaryngology - Head and Neck Surgery (AAO-HNSF): CORE Grants Various Opportunities||Please see individual funding opportunity description.||GSK Research Grant Social Determinants of Health (SDOH), Diversity/Equity/Inclusion (DEI), and the intersection of patient care with workforce culture: This seeks investigators who will design and execute research projects that will study one or both components of patient care and workforce culture as it pertains to SDOH and DEI. Value: USD $25,000 for 1 year.|
AAO-HNSF Maureen Hannley Research Grant: Designed to fill "research gaps" identified by the AAO-HNSF clinical practice guideline panels. Value: USD $50,000 for 1-2 years.
AAO-HNSF Health Services Research Grant: Proposed projects should be related to any area of otolaryngology-head and neck surgery and must have direct or potential clinical significance for patients seen by otolaryngologist-head and neck surgeons. Value: USD $10,000 for 1 year.
AAO-HNSF Bobby R. Alford Endowed Research Grant: Supports innovative research in the specialty and help facilitate the career development of young investigators. Applicants may be independent practitioners or practitioners affiliated with academic or similar institutions who have completed their residency within the past 7 years. Value: USD $30,000 for 1 year.
AHNS/AAO-HNSF Young Investigator Combined Award: this supports esearch project byfostering the development of contemporary basic or clinical research skills focused on neoplastic disease of the head and neck among new full-time academic head and neck surgeons Priority will be given to fellows or junior faculty who have completed residencies or fellowships within 4 years of the application receipt date. Value: USD $40,000 for 2 years.
AHNS/AAO-HNSF Translational Innovator Combined Award: This supports contemporary basic or clinical research focused on neoplastic disease by full time academic head and neck surgeons; to promote novel translational research, preferably with biomarker ideas. Value: USD $80,000 for 2 years.
AHNS Presidential Award: Understanding Long-Term and Late Toxicities of Treatment in Head and Neck Cancer: This supports research projects on the assessment and management of long-term and late physical, psychosocial, and financial toxicities among head and neck cancer survivors or their caregivers. These studies can be basic, translational, or clinical in nature. Value: USD $10,000 for 1 year.
AHNS Presidential Award: Understanding Treatment Resistance in Head and Neck Cancer: Any study in head and neck cancer that utilizes genomics, immune profiling, mechanistic approaches, or animal models to understand how such mechanisms might develop and how we might predict the presence/absence of resistance phenotypes prior to treatment is eligible for this award. Value: USD $10,000 for 1 year.
AHNS Presidential Award: Head and Neck Cancer in Underserved Populations: The topics can be centered on (but are not limited to): access to care, care delivery, quality of life outcomes, economic analyses, behavior/attitudes towards treatment, selection bias, educating patients, screening, surveillance. Value: USD $10,000 for 1 year.
AHNS/AAO-HNSF Young Investigator Combined Award: Supports a research project by fostering the development of contemporary basic or clinical research skills focused on neoplastic disease of the head and neck among new full-time academic head and neck surgeons. Priority will be given to fellows or junior faculty who have completed residencies or fellowships within 4 years of the application receipt date. Value: $40,000 for 2 years.
AHNS/AAO-HNSF Translational Innovator Combined Award: Supports contemporary basic or clinical research focused on neoplastic disease by full time academic head and neck surgeons; to promote novel translational research, preferably with biomarker ideas. Value: $80,000 for 2 years.
American Rhinologic Society (ARS) New Investigator Award: Supports basic, translational, or clinical research projects in rhinology. Value: USD $20,000 per year for 2 years.
ARS Friends in Research Award: Both early and mid-career investigators are encouraged to apply. Supports basic, translational, or clinical research projects in rhinology. Value: USD $12,500 per year for 2 years.
ARS Sue Ann and John L. Weinberg Foundation Cystic Fibrosis Chronic Rhinosinusitis Grant: Proposed projects must be related to the management of cystic fibrosis related chronic rhinosinusitis. Projects may be clinical, translational, or basic science in nature. Value: USD $20,000 for 2 years.
|Letters of Intent: December 16, 2022.
Applications: January 17, 2023.
|International||Lloyd's Register Foundation (LRF): Turning the 2021 world risk poll into action||Up to £250,000||LRF is inviting proposals for impactful research and interventions that will increase the utility and influence of data generated by the 2021 World Risk Poll Findings around global perceptions and experiences of risk in the Covid age. This call invites proposals from anywhere in the world to use the data to support impactful projects which are analytical or interventions-based, with the aim of improving safety among at-risk demographic groups across the LRF mission-aligned safety challenges.||December 31, 2022.|
|International||Society of Nuclear Medicine and Molecular Imaging (SNMMI): Various Opportunities||Please see individual funding opportunity description.||2022 Mitzi & William Blahd, MD, Pilot Research Grant: The pilot research grant is designed to help a basic or clinical scientist in the early stages of their career conduct research that may lead to further funding. Applicant must be no more than five years post training (most recent training; training includes residency, MD/PhD training, professional school, graduate school, post doc, or fellowship). Value: USD $25,000 for 1 year. |
2023-2025 ERF-SNMMI Molecular Imaging Research Grant for Junior Academic Faculty: To support one junior faculty member in an academic/research setting, and to enable them to engage in molecular imaging research related to diagnostic or therapeutic applications. Applicant must be a SNMMI member and must be in the first term of their academic appointment, with a rank no higher than assistant professor (or equivalent). Value: USD $52,500 per year for 2 years.
|January 2, 2023.|
|International||National Multiple Sclerosis Society (NMSS)||USD $800,000 over one to two years.||The NMSS invites pre-applications for its call on therapeutic development opportunities addressing nervous system repair in multiple sclerosis. This supports research partnerships with the society's commercial development programme, Fast Forward LLC, to accelerate and support development of therapeutic strategies and biomarkers relevant to the roadmap priority of nervous system repair in multiple sclerosis. A brief pre-application is required to determine if a proposal is aligned with the objectives of the RFA. Research areas NOT supported by this RFA: |
- New target identification studies
- High-throughput screening and early hit characterization
- Drug repurposing efforts without a commercially appropriate intellectual property strategy
|Pre-Application: up until January 4, 2023.
Full Proposal: January 11, 2023.
|International||American Association for Cancer Research (AACR) Career Development Awards in Lung Cancer Research||USD $250,000 over 2 years.||This is to encourage and support early-career investigators to conduct lung cancer research and establish successful careers in this field. The proposed project may be basic, translational, clinical, or epidemiological in nature and must have direct applicability and relevance to lung cancer. Applicants must be AACR Active members. Applicants must have a doctoral degree (PhD, MD, MD/PhD, or equivalent) and at the start of the grant term on July 1, 2023: hold a faculty position with the title of assistant professor, instructor, research assistant professor, or the equivalent; have completed their most recent doctoral degree within the past 11 years.||January 5, 2023.|
|International||Pfizer Global Medical Grants (GMG) - Global Cachexia ASPIRE||Up to USD $250,000||The intent of this RFP is to support research projects in the following categories: Evidence generation in Understanding Cachexia/Unintentional Weight Loss in Cancer or Heart Failure; Role of GDF-15/GFRAL Pathway in Disease; GDF-15/GFRAL Biology; Natural History (longitudinal) studies specifically related to cachexia/weight loss and/or heart failure||January 5, 2023.|
|International||Intuitive Foundation Clinical Research Grants for Robotic-Assisted Surgery||Up to USD $60,000 per project.||These grants support clinical research at non-profit institutions worldwide focused on the field of robotic-assisted surgery. Successful proposals will study important questions related to surgical care and patient outcomes.||Letter of Intent: January 6, 2023.
Full Proposal (by invitation): April 7, 2023.
|International||Radiological Society of North America (RSNA) Research & Education (R&E) Foundation: Various Opportunities||Please see individual funding opportunity description.||Education Project Award: This provides supplemental funding for new or ongoing education projects. Some examples may be projects that promote innovative teaching methodologies, resources or delivery evaluation mechanisms. You must be an RSNA member to apply. Value: Between USD $10,000 - $20,000 for a 1-year project.|
Derek Harwood-Nash International Education Scholar Grant: This provides funding for investigators whose focus is advancing radiologic education with an international scope. These projects have the potential to affect radiology students around the world for years to come. You must be an RSNA member to apply. Value: Up to USD $75,000 for a 1-year project.
RSNA/AUR/APDR/SCARD Radiology Education Research Development Grant: This grant encourages innovation and improvement in health sciences education by providing research opportunities to individuals in pursuit of advancing the science of radiology education. You must be a member of at least one of the sponsoring organizations to apply. Value: Up to USD $10,000 for a 1-year project.
|January 11, 2023.|
|International||Thrasher Research Fund E.W. "Al" Thrasher Awards||Up to USD $550,000.||Ideal applications address significant health problems, offering the potential for practical solutions to these problems. Typically, the primary outcome is a health outcome in children. Solutions should be innovative and have the potential for broad applicability with low barriers to implementation. Projects with a shorter distance to clinical applicability are given priority. Hypothesis-driven research is critical; exploratory, or hypothesis-generating research will not be competitive. For projects focused on improving disease diagnosis, please ensure that there are well researched, effective treatment options available to patients upon diagnosis.||Concept Paper: January 17, 2023; July 18, 2023.
Full Proposal (by invitation): April 21, 2023; October 20, 2023.
|International||American Association for the Study of Liver Diseases (AASLD): Bridge Award||USD $100,000 for 1 year.||This supports investigators who have recently submitted an NIH R or other federally funded equivalent award and have received competitive scores on their proposal, but were not funded. Applicants must be at or below the rank of Associate Professor.||January 23, 2023.|
|International||Pfizer Global Medical Grants (GMG) Quality Improvement Grant Request for Proposals (RFP): Optimizing Canadian Telehealth Use for Women's Health||Up to $30,000.||The Virtual Care Task Force (VCTF) created by the CMA, the CFPC and the RCPSC recently issued a report that highlights two issues: "Equity" and "The Appropriateness of Virtual Care". Pfizer indends to to support Quality Improvement initiatives that enhance the women's health virtual quality of care by focusing on equity and appropriateness of virtual care.||January 30, 2023.|
|International||Massage Therapy Foundation (MTF) Research Grants||MTF Research Support Grant: Up to USD $30,000 for 1 year.|
MTF Research Award: Up to USD $300,000 for up to 3 years.
|Awards are granted to support high quality, independent research which contributes significantly and directly to the knowledge of massage therapy and/or its application. Basic, applied, and translational research studies which investigate massage therapy as a wellness, medical, or health/mental health treatment and/or prevention intervention are supported.||MTF Research Support Grant: Deadline: February 1, 2023.
MTF Research Award: Pre-proposal: March 1, 2023. Full Proposal (by invitation): August 1, 2023.
|International||North American Spine Society (NASS): Various Opportunities||USD $20,000-$40,000 per year for 1 to 2 years.||NASS supports basic, clinical and translational science. The goal is to improve quality spine care for patients and understanding of underlying disorders. The Principal Investigator is required to be a NASS member.|
- Research Grants: Provide funding for promising research projects by qualified investigators in the field of spine.
- Young Investigator Grants: Principal investigators may be any age. MD applicants must be within five years of completion of training at the time of application; PhD applicants must be within five years of their post-doc training.
- Nontraditional Nonsurgical Treatment Grants: Supports research of disc-related and/or neuropathic back pain by nonsurgical techniques. These funds must be used for new, nontraditional methods of nonsurgical treatment of such back and neck pain and radiculopathy.
|Letter of Proposal: February 6, 2023.
Full Proposal (by invitation): May 8, 2023.
|International||Society for Vascular Surgery (SVS) Foundation Clinical Research Seed Grants||USD $25,000 for 1 year.||This supports clinical investigation in vascular disease, preferably patient-oriented: research conducted with human subjects or on material of human origin such as tissues, specimens and cognitive phenomena for which an investigator directly interacts with human subjects. Small-scale clinical trials and ancillary studies in the setting of existing clinical trials (industry or NIH-supported) will be accepted.|
The PI must be 1) an SVS Active Member within the first 10 years of practice or 2) a fellowship- or integrated residency-trained, board-eligible, vascular surgeon within the first 10 years of practice with a full-time faculty position with an SVS Active Member serving as mentor.
|March 1, 2023.|
|International||International Center for Responsible Gaming (ICRG): Request for Applications on the Impact of Gambling Advertising||Up to USD $172,500 for 2 years.||This is to study the impact of gambling advertising, including television, digital and push notifications. The goal of this initiative is to determine the aspects of advertising that might promote risky or problematic gambling attitudes and behaviors and provide metrics for the development of advertising guidelines for gambling operators and regulators.||March 1, 2023.|
|International||Biogen: Various Opportunities||--||Biogen considers requests in Biosimilars (Dermatology, Gastroenterology, Ophthalmology, Rheumatology), Multiple Sclerosis, and Spinal Muscular Atrophy in these areas: |
Medical Education: Supports independent medical educational activities for HCPs and researchers. Medical education may be accredited or non-accredited.
Patient Education: Supports independent educational activities for patients or caregivers.
General Grant: Supports a project or program that does not fit any of the other defined grant categories.
|February 15, May 15, August 15, November 1|
|International||JDRF Strategic Research Agreements||The budget and duration of funding are variable.||These provide research funding for single or multiple investigators to address critical gaps and challenges and potential breakthroughs in Type 1 diabetes research. The Strategic Research Agreement is a partnership between Investigator(s) and JDRF Scientists to help address roadblocks and accelerate JDRF's mission through support of cutting-edge scientific investigation. Further, this mechanism embodies cooperative development of a research plan, interim quarterly reporting on milestones and interaction with JDRF scientists prior to and during the award period.||May 3, 2023.|
|International||Alzheimer's Association: International Research Grant Program||--||Multiple Opportunities||Various
|International||Solving Kids Cancer (SKC): Therapeutic Development Initiative (TDI) - Funding for High-Impact Pediatric Cancer Research||$50,000 to $500,000 USD for up to 2 years.||The TDI of SKC only supports clinical research.||Preliminary Proposal Deadline: Ongoing|
|International||Össur Orthopaedic Research Grant Program||--||This provides funding for scientific inquiry in the areas of lower extremity biomechanics, dynamic/active rehabilitation, ortho biologics, functional bracing, clinical patient outcomes, and, related healthcare economics.||Rolling Deadline|
|International||Gateway for Cancer Research (GFCR): Various Opportunities||GFCR Grant Program: USD $200,000 to $1.5 million for 2-5 years|
GFCR Integrative Program:USD $200,000 to $1.5 million for 2-5 years.
SIO / Gateway Integrative Research Grant Program: Value: USD $200,000 to $1.5 million for 2-5 years.
|Gateway funds Phase I and II patient-centered cancer clinical trials that have the potential to shift the paradigm for standard of care, focusing on the following priority research areas: Biomarkers/Molecular Markers (genomic or proteomic); Gene Therapy; Histology Agnostic/Basket Trial; Immunotherapy; Targeted Therapies. Focus is on the following therapeutic areas: New Investigational Therapies; Novel Use or Approach; Precision Medicine; Integrative Medicine.|
GFCR Grant Program: Funds early phase clinical trials for cancers of all types at renowned institutions around the world.
GFCR Integrative Program: Funds integrative oncology research that pairs conventional therapies with evidence-based integrative therapies to manage symptoms and side effects from treatment. This also aims to increase quality of life, especially post-treatment.
SIO / Gateway Integrative Research Grant Program: Funds integrative oncology research that pairs conventional therapies with evidence-based integrative therapies to manage symptoms and side effects from treatment. This also aims to increase quality of life, especially post-treatment.
GFCR Decentralized (DCTI) Grant Program: Leverages site-less, technology-informed trials, with the objective of bringing clinical trials directly to patients doorsteps.
|GFCR Grant Program: Rolling Deadline
GFCR Integrative Program:Rolling Deadline
SIO / Gateway Integrative Research Grant Program: Rolling Deadline
|International||Aesculap Implant Systems Investigator-Initiated Study Program (IIS)||--||This supports researchers interested in conducting studies of their own design, which promotes the advancement of medical and scientific knowledge related to Aesculap's products and therapeutic areas of focus: Neurosurgery; Surgical Technologies; Closure Technologies; Orthopaedics; Spine; Biologics.||Continuous intake|
|International||Bausch + Lomb Grants||--||Educational Grants: These contribute to the improvement of patient care and advances in the use of healthcare products. Grand-rounds, lectures, symposiums and workshops are funded to educate medical students, university faculty, physicians, nurse practitioners, optometrists, ophthalmologists, allied health professionals, optical research scientists and associations of optometry and ophthalmology about improvements in ocular health.|
Independent Research Grant: These empower the global research community to develop new treatments and technological advancements in ocular health. Research Grants have been funded by to improve consumers' standard of care, efficacy, patient satisfaction, safety and vision performance.
|Rolling submission. Allow 6-12 weeks for proposal review and decision.|
|NIH||NIH Transgender People: Immunity, Prevention, and Treatment of HIV and STIs (R21 Clinical Trial Not Allowed)||--||This supports hypothesis-generating research in transgender people with the objective of characterizing the biological and immunological impact of the interventions (hormones, drugs and surgical) used for gender reassignment and their impact on susceptibility to HIV and other sexually transmitted infections (STI).||December 7, 2022; December 7, 2023; December 7, 2024.|
|NIH||NIH BRAIN Initiative: Theories, Models and Methods for Analysis of Complex Data from the Brain (R01 Clinical Trial Not Allowed)||--||This seeks the development of theories, computational models, and analytical tools to derive understanding of brain function from complex neuroscience data. Proposed projects could develop tools to integrate existing theories or formulate new theories; conceptual frameworks to organize or fuse data to infer general principles of brain function; multiscale/multiphysics models to generate new testable hypotheses to design/drive future experiments; new analytical methods to substantiate falsifiable hypotheses about brain function.||December 15, 2022; September 12, 2023; September 12, 2024.|
|NIH||NIH Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer||--||This intends to focus on basic mechanistic and translational studies to investigate HIV and cancer in underrepresented groups. Underrepresented groups include racial, ethnic, and gender minorities, including underserved minorities living in geographical areas that have high numbers of new HIV infections (e.g., Southern and some urban areas in the United States, international sites that have higher rates of underlying HIV infection). Mechanistic and/or translational studies that examine how different comorbidities, associated behaviors, and other disorders (e.g., diabetes, smoking, injecting drug users, obesity, etc.), contribute to the initiation, progression and disease sequelae in underserved populations may be proposed. |
- R21 Clinical Trial Not Allowed
- R01 Clinical Trial Not Allowed
|December 15, 2022; December 15, 2023.|
|NIH||NIH Urgent Awards: COVID-19 Mental Health Research||--||These aims to address urgent, time-sensitive mental health research questions related to COVID-19, including broader secondary impacts of the pandemic as well as research on the intersection of mental health, COVID-19, and HIV. Research supported will improve public health in the near term by informing responses to the current pandemic.|
- R01 Clinical Trial Optional: Supports 1) understanding mechanisms by which mental illness impacts SARS-CoV-2 morbidity and mortality, 2) exploring how COVID-19 contributes to incident mental illness or HIV-outcomes, 3) identifying modifiable targets uniquely or robustly implicated in the pandemic that are relevant to new and worsening mental illness, and 4) conducting mechanistic trials probing biological or behavioral processes of those targets that may be pursued in future mental health therapeutic development.
- R01 Clinical Trial Required: Supports research to address access, reach, delivery, effectiveness, scalability and sustainability of health assessments and interventions to respond to new and worsening mental illness and HIV-related outcomes among those who experience COVID-19 as well as the broader population impacted by the pandemic.
|December 23, 2022.|
|NIH||NIH Notice of Special Interest (NOSI): Complement in Basic Immunology (CIBI)||--||This supports studies that accelerate our understanding of the roles of complement components and/or receptors in the initiation, magnitude, maintenance, and quality of immune responses against infectious agents, or of the roles played by complement in the development of immune-mediated pathogenic responses following infection. The results of such studies will inform the development of adjuvants and vaccine candidates or therapeutics that target complement components.||This notice applies to subsequent receipt dates through January 7, 2023.|
|NIH||NIH Innovations in HIV Prevention, Testing, Adherence and Retention to Optimize HIV Prevention and Care Continuum Outcomes||--||This seeks innovative research to optimize HIV prevention and care which is aligned with National Institute of Mental Health (NIMH) Division of AIDS Research (DAR) priorities. Applications may include formative basic behavioral and social science to better understand a step or steps in the HIV prevention or care continuum, and/or the initial development and pilot testing of innovative intervention approaches.|
R21 Clinical Trial Optional: High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism.
R01 Clinical Trial Optional: Applicants with preliminary data and/or including longitudinal analysis may apply using the R01 mechanism.
|Standard AIDS dates apply until January 8, 2023.|
|NIH||NIH Notice of Special Interest (NOSI): Opportunities for HIV Cure Interventions at the Time of ART Initiation||--||The scientific objective of this NOSI is to support projects to explore HIV cure approaches administered during active HIV/SHIV/SIV infection, prior to or around the time of antiretroviral therapy (ART) initiation, before viral loads are completely suppressed, to potentially enhance the ongoing immune response and prevent additional reservoir seeding. A better understanding of the decay dynamics of various virus-infected cell subsets following ART initiation is also needed.||This notice applies to due dates on or after January 7, 2023 and subsequent receipt dates through September 7, 2025.|
|NIH||NIH Notice of Special Interest (NOSI): Opportunities for HIV Cure Interventions at the Time of ART Initiation||--||The scientific objective is to support projects to explore HIV cure approaches administered during active HIV/SHIV/SIV infection, prior to or around the time of ART initiation, before viral loads are completely suppressed, or after an analytical treatment interruption to potentially enhance the ongoing immune response and prevent additional reservoir seeding. The curative approaches studied should be experimental, innovative, and not yet approved by the FDA or a foreign regulatory agency for an HIV indication.||This notice applies to due dates on or after January 7, 2023 and subsequent receipt dates through September 7, 2025.|
|NIH||NIH Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)||__||Through this, National Cancer Institute (NCI) wishes to stimulate research in 1) discovery and development of novel, small molecules for their potential use in studying disease treatment relevant to the missions of the participating NIH Institutes [National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Mental Health (NIMH)], and 2) generation of new insight into the biology of relevant diseases and processes that have yet to be validated as important drug targets. Projects may focus on one stage, or span several stages of discovery research: 1) assay development; 2) primary screen implementation; 3) hit validation; and 4) hit-to-lead optimization.||Standard dates apply until January 8, 2023.|
|NIH||NIH Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R21)||--||The goal of this initiative is to address key scientific questions relevant to cancer genomic and epidemiology by supporting the analysis of existing genetic or genomic datasets, in combination with other omics and environmental, clinical, behavioral, lifestyle, and molecular profiles data. Applicants are encouraged to leverage existing genetic data and perform innovative analyses of the existing data.||Standard dates apply until January 8, 2023.|
|NIH||NIH Co-infection and Cancer|
- PAR-20-062 (R01 Clinical Trial Not Allowed)
- PAR-20-061 (R21 Clinical Trial Not Allowed)
|--||The purpose is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents - either concurrently or sequentially- and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and of co-infections that engender novel opportunities for prevention and treatment.||Standard dates apply until January 8, 2023.|
|NIH||NIH Fundamental Mechanisms of Affective and Decisional Processes in Cancer Control (R01 Clinical Trial Optional)||--||This encourages projects to generate fundamental knowledge of affective processes. Basic affective science projects should have key consequences for single (e.g., cancer screening) and multiple (e.g., adherence to oral chemotherapy regimen) event decisions and behaviors across the cancer prevention and control continuum. This is expected to encourage collaboration among cancer control researchers and those from scientific disciplines not traditionally connected to cancer control applications (e.g., affective and cognitive neuroscience, decision science, consumer science) to elucidate perplexing and understudied problems in affective and decision sciences with downstream implications for cancer prevention and control.||Standard dates apply until January 8, 2023.|
|NIH||NIH Notice of Special Interest (NOSI): Promoting Pain Research Within the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Mission Areas||--||This NOSI invites research applications that focus on improving the understanding of mechanisms of acute and chronic pain, and enhancing knowledge that will help better prevent, manage and reduce pain and improve health equity of all populations suffering from acute or chronic pain caused by rheumatic, autoinflammatory, musculoskeletal, and skin diseases and conditions within the NIAMS mission.||This notice applies to subsequent receipt dates through January 10, 2023.|
|NIH||NIH Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)||--||The primary objective is to move Digital Therapeutics (DTx) to their next step in the development process, with the ultimate goal of generating new, FDA authorized, disseminated treatments for Substance Use Disorders (SUDs). Applications may focus on the pre-clinical and/or clinical development and testing of new DTx or existing DTx developed for other indications.||January 10, 2023; September 8, 2023; January 10, 2024.|
|NIH||NIH Maintaining Immunity after Immunization (U01 Clinical Trial Not Allowed)||--||Applications are sought that propose to (1) define the immune mechanisms and components that lead to sustained immunity, and/or (2) identify common versus distinct durable immune mechanisms triggered by vaccines compared to natural infection. Findings from this research will contribute to a more complete understanding of the requirements for vaccine-induced durable protection. Applications must propose the use of human cells/tissues to decipher the human response elicited through vaccination. Animal studies also may be included to elucidate mechanistic pathways not easily accomplished with human samples.||January 13, 2023.|
|NIH||NIH - Notice of Special Interest (NOSI): Research through NCATS' Clinical and Translational Science Award (CTSA) Program: High Impact Specialized Innovation Programs (RC2)||--||This NOSI focuses on the following area: Digital Health Technologies (DHT) that can be adopted and implemented for clinical and translational research, like wearables, mobile health (mHealth apps), ambient sensors, health information technology (IT), and other software as a medical device (SaMD) solutions. Appropriate topics include, but are not limited to the following: DHT platforms, tools, or resources to help de-centralize clinical trials; Procedures, methods, and clinical workflow integration that enable the rapid dissemination of DHT to multiple diverse communities and/or to geographically isolated, medically underserved, and otherwise vulnerable populations; DHT platforms, tools, or resources to enable more objective understanding, earlier mitigation, and/or longer-term monitoring for adverse events or side effects from treatment; DHT for adaptive clinical trial design (proactive patient stratification); Enhancing clinical and translational research, including the ability to collect and analyze large data sets and implement innovative DHT solutions that improve human health through Real-World Data and Real-World Evidence.||This notice applies to due dates on or after January 13, 2023 and subsequent receipt dates through January 12, 2024.|
|NIH||NIH Using Just-in-Time Adaptive Interventions to Optimize Established Adolescent Mental Health Treatments (R61/R33 Clinical Trial Required)||--||This seeks research to promote rapid development of analytical methods and tools to assess the prevalence of emerging illicit drugs and thereby understand their health impacts. It is anticipated that applicants will propose to develop assessment technologies to improve assessment of emerging drug threat prevalence in multiple environments.||February 2, 2023.|
|NIH||NIH HEAL Initiative: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed)||_||The focus is on the basic science discovery of targets in the peripheral nervous system, central nervous system, immune system or other tissues in the body that can be used to develop treatments that have minimal side effects and little to no abuse/addiction liability. Research supported must include rigorous validation studies to demonstrate the robustness of the target as a pain treatment target.||February 2, 2023; June 2, 2023; October 4, 2023; February 2, 2024; June 4, 2024; October 2, 2024.|
|NIH||NIH Innovative Mental Health Services Research Not Involving Clinical Trials (R01 Clinical Trials Not Allowed)||--||This encourages innovative research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness.||February 5, 2023; June 5, 2023; October 5, 2023; February 5, 2024; June 5, 2024.|
|NIH||NIH Dissemination and Implementation Research in Health: Various Opportunities||--||Supports studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce ("de-implement") the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged.|
- R01 Clinical Trial Optional
- R03 Clinical Trial Not Allowed
- R21 Clinical Trial Optional
|R01 Clinical Trial Optional: February 5, 2023; June 5, 2023; October 5, 2023; February 5, 2024; June 5, 2024; October 5, 2024; February 5, 2025.
R03 Clinical Trial Not Allowed: February 16, 2023; June 16, 2023; October 16, 2023; February 16, 2024; June 16, 2024; February 16, 2025; June 16, 2025.
R21 Clinical Trial Optional: February 16, 2023; June 16, 2023; October 16, 2023; February 16, 2024; June 16, 2024; February 16, 2025; June 16, 2025.
|NIH||NIH National Library of Medicine (NLM) Research Grants in Biomedical Informatics and Data Science (R01 Clinical Trial Optional)||--||This focuses on biomedical discovery and data-powered health, integrating streams of complex and interconnected research outputs that can be translated into scientific insights, clinical care, public health practices, and personal wellness. The scope of NLM's interest in these research domains is broad, with emphasis on new and innovative methods and approaches to foster data driven discovery in the biomedical and clinical health sciences as well as domain-independent, scalable, and reusable/reproducible approaches to discovery, curation, analysis, organization, and management of health-related digital objects.||February 5, 2023; June 5, 2023; October 5, 2023; February 5, 2024; June 5, 2024; October 5, 2024; February 5, 2025; June 5, 2025; October 5, 2025.|
|NIH||NIH Notice of Special Interest (NOSI): Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R01, R21, R03)||--||National Institute on Drug Abuse (NIDA) seeks research on rigorous hypothesis-driven and theory-based study designs and data analytic methods that will support a new generation of patient centered addiction health services research.||This notice applies to due dates on or after February 5, 2023 and subsequent receipt dates through January 8, 2026.|
|NIH||NIH Notice of Special Interest (NOSI): Explainable Artificial Intelligence for Decoding and Modulating Neural Circuit Activity Linked to Behavior||--||The eXplainable Artificial Intelligence (XAI) framework aims to provide strong predictive value along with a mechanistic understanding of AI solutions by combining machine learning techniques with effective explanatory techniques. This NOSI solicits applications in the area of XAI applied to neuroscientific questions of encoding, decoding, and modulation of neural circuits linked to behavior. This NOSI encourages collaborations between computationally and experimentally focused investigators. This NOSI seeks the development of machine learning algorithms that are able to mechanistically explain how experimental manipulations affect cognitive, affective, or social processing in humans or animals.||This notice applies to due dates on or after February 5, 2023 and subsequent receipt dates through February 5, 2026.|
|NIH||NIH NINDS Exploratory Clinical Trials (UG3/UH3 Clinical Trial Required)||--||This is for investigator-initiated exploratory Phase 1 and Phase 2 clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). These trials must address questions within the mission and research interests of the NINDS. They may include studies of drugs and biologics, feasibility or preliminary efficacy studies of devices, and early studies of surgical, behavioral or rehabilitation therapies.||February 8, 2023; June 13, 2023; October 10, 2023; February 8, 2024; June 10, 2024; October 8, 2024; February 10, 2025.|
|NIH||NIH NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required)||--||This is to encourage grant applications for investigator-initiated efficacy clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies.||February 9, 2023; June 9, 2023; October 10, 2023; February 9, 2024.|
|NIH||NIH Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)||--||The National Cancer Institute (NCI) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial.||February 10, 2023; June 13, 2023; October 11, 2023; February 13, 2024; June 11, 2024; October 11, 2024.|
|NIH||NIH Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)||--||The National Cancer Institute (NCI) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. Research on non-cancer outcomes, especially those related to aging (e.g., Alzheimer's, depression, hip fracture, osteoporosis and rheumatoid arthritis) may also be supported.||February 10, 2023; June 13, 2023; October 11, 2023; February 13, 2024; June 11, 2024; October 11, 2024.|
|NIH||NIH Multi-Site Investigator-Initiated Clinical Trials: Various Opportunities||--||These support investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which must be relevant to the research mission of the National Heart, Lung, and Blood Institute (NHLBI).|
Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)
Both a DCC application and a collaborating CCC application must be submitted on the same application due date for consideration by NHLBI.
|February 10, 2023; June 13, 2023; October 11, 2023; February 13, 2024; June 11, 2024; October 11, 2024; February 11, 2025; June 11, 2025.|
|NIH||NIH Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)||--||This supports applications to develop and implement investigator-initiated single site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials must be relevant to the research mission of the National Heart, Lung, and Blood Institute (NHLBI).||February 10, 2023; June 13, 2023; October 11, 2023; February 13, 2024; June 11, 2024; October 11, 2024; February 11, 2025; June 11, 2025.|
|NIH||NIH Dementia Care and Caregiver Support Intervention Research||--||R01 Research Project Grant - Clinical Trial Required: This solicits mechanism-focused dementia care and caregiver support intervention development research at Stages I through V of the NIH Stage Model to address the care needs and promote the health, function, and well-being of persons with Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD) and of those providing their care.|
R61/R33 - Clinical Trial Required: This will support pragmatic trials within Stage IV of the NIH Stage Model to improve dementia care across multiple dementia care settings. This will support Stage I or Stage III pilot research to test the feasibility of implementing and integrating interventions (R61 phase) that, if successful, can transition to an R33 phase (Stage IV) for implementation of large pragmatic trials.
|February 10, 2023; October 10, 2023; February 13, 2024.|
|NIH||NIH NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)||--||This supports preclinical and early phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, comparative oncology, symptom management, or reduction of cancer disparities. It does not support research that focuses on basic cancer biology (such as studies of cancer-related pathways, molecular mechanisms, or mechanisms of metastasis), late-stage clinical trials, risk assessment studies, epidemiological studies, or studies of behavioral interventions.||February 13, 2023; June 12, 2023; October 10, 2023; February 13, 2024; June 12, 2024; October 10, 2024; February 13, 2025; June 12, 2025.|
|NIH||NIH Tobacco Regulatory Science (R01 Clinical Trial Optional)||--||This supports biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP).||February 14, 2023.|
|NIH||NIH BRAIN Initiative: Brain-Behavior Quantification and Synchronization - Transformative and Integrative Models of Behavior at the Organismal Level (R34 Clinical Trial Not Allowed)||--||This seeks applications with limited scope proposing a set of planning activities that will lay the groundwork for a scientific project aimed at integrating complementary theories and methods to 1) develop, validate, and apply cutting-edge tools and methods for minimally invasive, multi-dimensional, high-resolution measurement of behavior at the level of the organism, with synchronous capture of changes in the organism's social or physical environment; and/or 2) develop computational methods that allow for integration of multidimensional behavioral and environmental data representing multiple timescales into a conceptual and/or computational model of behavior as a complex dynamic system, designed with the capacity to integrate synchronously recorded neural data and/or inform existing models of neurobehavioral function, such as those developed with the support of the NIH BRAIN Initiative.||February 14, 2023.|
|NIH||NIH National Institute of Mental Health (NIMH) Clinical Trial Funding Opportunity Announcements (FOAs): Various Opportunities||--||NIMH solicits clinical trial applications through a series of FOAs that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials.|
- PAR-21-129: Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01 Clinical Trial Required)
- PAR-21-130: Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01 Clinical Trial Required)
- PAR-21-131: Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34 Clinical Trial Required)
- PAR-21-132: Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required)
- PAR-21-134: Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required)
- PAR-21-135: Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required)
- PAR-21-136: Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)
- PAR-21-137: Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)
|February 15, 2023; June 15, 2023; October 17, 2023; February 15, 2024.|
|NIH||NIH HIV/AIDS High Priority Drug Abuse Research (R01 Clinical Trial Optional)||--||This supports high priority research at the intersection of HIV and substance use. It is open to both individual researchers and research teams and includes all areas of research from basic science to clinical and implementation research.||February 15, 2023; August 15, 2023; February 15, 2024.|
|NIH||NIH - Notice of Special Interest (NOSI): Small Research Grants for Innovations in Healthy Longevity Research||--||The National Institute on Aging's (NIA) is interested in projects that reflect its mission to support research on aging, the aging process, and diseases and conditions associated with growing older, including Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Applications that reflect NIA's programmatic interests in genetic, biological, clinical, epidemiological, neuroscience, behavioral, social, and economic research on aging as they relate to healthy longevity are encouraged.||This notice applies to due dates on or after February 16, 2023 and subsequent receipt dates through May 8, 2023.|
|NIH||NIH Prospective Observational Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed)||--||The study must address questions within the mission and research interests of the National Institute of Neurological Disorders and Stroke (NINDS) and may evaluate preventive strategies, diagnostic approaches, or interventions including drugs, biologics, and devices, or surgical, behavioral, and rehabilitation therapies. NINDS is particularly interested in pragmatic study designs that utilize a cost-effective means of prospectively collecting observational data important to current clinical practice.||February 17, 2023; June 19, 2023; October 18, 2023; February 20, 2024; June 18, 2024; October 18, 2024; February 19, 2025.|
|NIH||NIH Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases (U01 Clinical Trial Not Allowed)||--||This invites researchers to submit applications for support of clinical studies that address critical needs for clinical trial readiness in rare neurological and neuromuscular diseases. These studies should result in clinically validated biomarkers and clinical outcome assessment measures appropriate for use in upcoming clinical trials.||February 17, 2023; August 17, 2023; February 20, 2024; August 19, 2024; February 19, 2025.|
|NIH||NIH Ethical, Legal and Social Implications (ELSI) Research: Various Opportunities||--||R01 Clinical Trial Optional: Applications may propose studies using either single or mixed methods. Proposed approaches may include but are not limited to data-generating qualitative and quantitative approaches, legal, economic and normative analyses, and other types of analytical and conceptual research methodologies, such as those involving the direct engagement of stakeholders. |
R21 Clinical Trial Optional: These applications should propose single or mixed methods studies that break new ground, extend previous discoveries in new directions or develop preliminary data in preparation for larger studies. Of particular interest are studies that explore the implications of new or emerging genomic technologies or novel uses of genomic information.
R03 Clinical Trial Optional: These applications should be for small, self-contained research projects, such as those that involve single investigators. Of particular interest are projects that propose normative or conceptual analyses, including focused legal, economic, philosophical, anthropological, or historical analyses of new or emerging issues. This mechanism can also be used for the collection of preliminary data and the secondary analysis of existing data.
|February 17, 2023; June 19, 2023.|
|NIH||NIH Translational Neural Devices (UG3/UH3 - Clinical Trial Optional)||--||This encourages investigators to pursue translational activities and small clinical studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. This is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress.||February 21, 2023; June 19, 2023; October 18, 2023; February 20, 2024.|
|NIH||NIH Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional)||--||This supports the phased development of in vivo assays to address translational gaps in treatment development for mental disorders. Support will be provided for assay development efforts that propose quantitative measures to assess alterations in neurophysiology/circuit activity that contribute to or reflect clinically relevant domains of function (e.g., cognitive function, impulsivity, motivation, etc.). It supports assays that measure brain functions that are evolutionarily conserved between a selected animal species and humans.||February 21, 2023; June 21, 2023; October 21, 2023; February 21, 2024; June 21, 2024; October 21, 2024; February 21, 2025; June 20, 2025.|
|NIH||NIH HEAL Initiative: Rapidly Assessing the Public Health Impact of Emerging Opioid Threats (UG1 - Clinical Trial Optional)||--||National Institute of Mental Health seeks applications for pilot research to develop and test just-in-time adaptive intervention augmentations to enhance the effectiveness and clinical potency of established adolescent mental health treatments. An emphasis is placed on studies that are informed by developmental science and grounded in an empirical model of behavior change.||February 22, 2023.|
|NIH||NIH Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional) ||--||This initiative intends to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors.||February 24, 2023; June 26, 2023; October 25, 2023; February 27, 2024; June 25, 2024; October 25, 2024; February 25, 2025; June 25, 2025.|
|NIH||NIH Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)||--||This encourages applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, and implementation science.||March 7, 2023; November 5, 2023; March 7, 2024.|
|NIH||NIH Accelerating the Pace of Drug Abuse Research Using Existing Data||--||This invites applications proposing innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance using behaviors (defined as alcohol, tobacco, prescription, and other substances) and related disorders, prevention of substance use and HIV, and health service utilization. Primary data collection is not allowed for applications.|
- R21 Clinical Trial Optional
- R01 Clinical Trial Optional
|March 7, 2023; August 9, 2023; November 15, 2023; March 4, 2024; August 5, 2024; November 15, 2024.|
|NIH||NIH HEAL Initiative: Discovery and Functional Evaluation of Human Pain-associated Genes and Cells (U19 Clinical Trial Not Allowed)||--||Supports research that uses human tissue or cells to generate comprehensive datasets for the discovery and characterization of functional genetic elements, epigenetic signatures, and molecular/cellular pathways that underlie human pain transduction, transmission, and processing.||March 9, 2023.|
|NIH||NIH Research on Current Topics in Alzheimer's Disease and Its Related Dementias||This invites applications proposing research on current topics in Alzheimer's disease (AD) and its related dementias (ADRD). Further information on the high-priority topics of interest will be announced through a series of Notices published subsequent to this announcement. Applications proposing research on topics beyond those specified in the notices will not be prioritized for funding.|
- R21 Clinical Trial Optional: For applications that need additional preliminary data with broader dissemination to establish them for more general use in this research field.
- R01 Clinical Trial Optional
|March 10, 2023; July 10, 2023; November 13, 2023; March 11, 2024; July 9, 2024; November 12, 2024.|
|NIH||NIH Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) (U19 Clinical Trial Not Allowed)||--||This will support technology transfer, preclinical immunogenicity and optimization studies, process development, analytical assay development, qualification, validation, testing, small scale pilot or engineering runs, CGMP manufacture in partnership with Pharma/ Biotech/Contract Manufacturing Organizations (CMO), quality assurance/quality control oversight, fill-finish activities, product release and storage, generation of reference standard, drug substance and drug product stability testing programs, Investigational New Drug (IND)-enabling studies, and regulatory submission preparation.||March 15, 2023; March 15, 2024; March 14, 2025|
|NIH||NIH Patient Activation for Self-Management of Chronic Conditions (R01 Clinical Trial Optional)||--||This encourages grant applications that address the influence of patient activation on self-management of chronic conditions.||AIDS Applications: May 7, 2023.
New Applications: February 5, 2023.
|NIH||NIH Notice of Special Interest (NOSI): Neurological and Neurocognitive Sequelae from SARS-CoV-2 Infection and COVID-19 in Aging and Age-Related Neurodegeneration||--||The specific research objectives of this NOSI are to rapidly expand the knowledge base on acute and long-term neurological and neurocognitive sequelae of COVID-19. NIA encourages investigator-initiated new and resubmission applications for research activity codes (i.e., R21, R01, R03) to address significant questions about the neurological and neurocognitive impacts of COVID-19 infection in aging and the interaction in older adults of COVID-19 with comorbid conditions, including Alzheimer's disease (AD) and AD-related dementias (ADRD).||This notice applies to subsequent receipt dates through May 7, 2023.|
|NIH||NIH Notice of Special Interest (NOSI): Heart, Lung, Blood and Sleep Focused Ancillary Studies to Large Ongoing Clinical Studies (Revised)||--||This seeks to expand the breadth of scientific research on the clinical course, prevention and treatment of diseases within the mission of the National Heart, Lung, and Blood Institute (NHLBI) by leveraging ongoing clinical research studies through ancillary studies. The purpose is to invite research project applications to conduct focused ancillary studies to large ongoing clinical trials (including late-stage T4 implementation clinical trials), observational studies, and registries.||This notice applies to subsequent receipt dates through May 8, 2023.|
|NIH||Notice of Special Interest (NOSI): Adopting Techniques and Tools Developed from the BRAIN Initiative Toward National Institute of Mental Health (NIMH) Strategic Research Priorities||--||NIMH is encouraging the submission of applications proposing to use the following types of tools/technologies developed in the BRAIN Initiative:|
- Technologies that enable causal in vivo behavioral neuroscience experimental designs to probe functions of neural circuits implicated in the above-mentioned behavioral domains
- Technologies that analyze and manipulate complex circuits with a goal to provide comprehensive circuit diagrams
- Technologies that monitor neural activity and in vivo behaviors
- Interventional tools
- Technologies that allow examination of developmental time course and/or sex differences in mental health-relevant circuit function
- Computational modeling approaches and data analysis
|This notice applies to receipt dates through May 8, 2023.|
|NIH||Notice of Special Interest (NOSI): Research on Rehabilitation Needs Associated with the COVID-19 Pandemic||--||The purpose of this NOSI is to encourage applications in three areas related to the intersection of COVID-19, the associated mitigation actions, and rehabilitation:|
- Encourage research to address the rehabilitation needs of survivors of COVID-19
- Understand the impact of disruptions to rehabilitation services caused by the COVID-19 pandemic and associated mitigation actions
- Understand the social, behavioral, economic, and health impact of the COVID-19 pandemic and the associated mitigation actions on people with physical disabilities
|This notice applies to receipt dates through May 8, 2023.|
|NIH||NIH National Eye Institute (NEI) Collaborative Clinical Vision Project: Various Opportunities||--||These support to support investigator-initiated large-scale clinical trials, human gene-transfer, stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials. The proposed study must be intended to evaluate interventions aimed at screening, diagnosing, preventing, or treating vision disorders, or to compare the effectiveness of two or more established interventions. |
Chair's Grant (UG1-Clinical Trial Required): This encourages applications for the Chair's grant, which includes the scientific rationale, study aims and significance of the research project.
Coordinating Center Grant (UG1 Clinical Trial Required):This encourages applications for the Coordinating Center grant, which provides details of the Coordinating Center's responsibilities and operations.
Resource Center Grant (UG1- Clinical Trial Required): This encourages applications for the Resource Center grant which provides imaging, laboratory, or other requisite services for a multi-center clinical trial or other complex or high-risk clinical trial.
|Standard dates apply until May 8, 2023.|
|NIH||NIH Notice of Special Interest (NOSI): Simulation Modeling and Systems Science to Address Health Disparities||--||The purpose is to support investigative and collaborative research focused on developing and evaluating simulation modeling and systems science (SMSS) to understand and address minority health and health disparities.||Standard dates apply until May 8, 2023.|
|NIH||NIH Notices of Special Interest (NOSI): Electronic Nicotine Delivery Systems (ENDS) and Alternative Nicotine and Tobacco Delivery Systems||--||The Office of Disease Prevention and participating Institutes, Centers and Offices (ICOs) are issuing this Notice to communicate our interest in research examining how electronic nicotine delivery systems (ENDS) affect normal and disease states relevant to human cells, tissues, organs, and behaviors. Research on alternative nicotine and tobacco delivery systems [e.g., heated tobacco products (also called heat-not-burn)] will also be considered.|| Basic Mechanisms of Health Effects:This Notice applies to subsequent receipt dates through May 9, 2023.
Population, Clinical and Applied Prevention Mechanisms of Health Effects:This Notice applies to subsequent receipt dates through May 9, 2024.
|NIH||NIH Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)||--||This solicits applications from research partnerships formed by academic and industrial investigators to accelerate the development and adoption of promising bioengineering tools and technologies that can address important biomedical problems. The goal of the program is to support technological innovations that deliver new capabilities, which can realize meaningful solutions within 5-10 years. Projects may span the development in the research settings, validation, translation into clinical settings as needed, and incorporation of these solutions as endpoints into research protocols to enhance our understanding of life science processes or the practice of medicine to benefit patients.||May 26, 2023; September 26, 2023; May 24, 2024; September 26, 2024.|
|NIH||NIH Exploratory Grants in Cancer Epidemiology (R21 Clinical Trial Optional)||--||This supports applications that focus on different aspects of cancer control by modifying behavior, screening, and understanding etiologic factors contributing to the development of cancer, and developing ways to control cancer. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance population-based cancer research, such as the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (e.g. epidemiologic, biomedical, behavioral, health care delivery or clinical).||June 7, 2023; October 9, 2023; June 7, 2024; October 8, 2024|
|NIH||NIH HEAL Initiative: Team Research for Initial Translational Efforts in Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed)||--||This supports interdisciplinary team-based research projects to develop assays, conduct screening and early optimization work followed by pharmacokinetic, pharmacodynamic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development. Discovery and validation of pharmacodynamic markers as well as development and validation of animal models or outcome measures are also responsive.||June 9, 2023; October 10, 2023.|
|NIH||NIH HEAL Initiative: Planning Studies for Initial Analgesic Development Initial Translational Efforts [Small Molecules and Biologics] (R34 Clinical Trial Not Allowed)||--||The goal of this funding opportunity announcement (FOA) is to solicit Initial Analgesic Development R34 applications that propose 2-year exploratory/planning awards. The limited scope of aims and approach of these applications are expected to establish a strong research team, feasibility, validity, or other technically qualifying results that support, enable, and/or lay the groundwork for a subsequent Team Research U19 application.||June 9, 2023; and October 10, 2023.|
|NIH||NIH HEAL Initiative: Team Research for Initial Translational Efforts in Non-addictive Analgesic Therapeutics Development (U19 Clinical Trial Not Allowed)||--||The goal of this funding opportunity announcement (FOA) is to support team-based research projects to develop assays, screening and early optimization work to develop a non-addictive therapeutic to treat pain. Discovery and validation of pharmacodynamic markers efficacy and pharmacokinetic / pharmacodynamic (PK/PD) studies are also responsive. This FOA is not specific for any one or group of pain conditions.||June 9, 2023; and October 10, 2023.|
|NIH||NIH Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery: Various Opportunities||--||This invites research projects that seek to explain the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in human health, illness, recovery, and overall wellbeing. |
- PAR-21-349 (R01 Basic Experimental Studies with Humans Required): Types of projects include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical and/or behavioral outcomes in humans to understand fundamental aspects of phenomena related to social connectedness and isolation. Applications should not propose a goal of clinical outcomes or products.
- PAR-21-350 (R01 Clinical Trials Not Allowed): For applications that propose studies including model animal research or observational studies involving humans. Both animal model and human subjects research projects are welcome; however, clinical trials are not allowed.
- PAR-21-352 (R01 Clinical Trial Required): Types of projects include mechanistic studies that are classified as clinical trials. Types of studies include clinical trials that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind.
|June 21, 2023; June 21, 2024.|
|NIH||NIH BRAIN Initiative: Targeted BRAIN Circuits Projects||--||- R34 Clinical Trials Not Allowed:For applications that offer a limited scope of aims and an approach that will establish feasibility, validity, or other technically qualifying||R34 Clinical Trials Not Allowed:: June 30, 2023; October 4, 2023; June 28, 2024; October 2, 2024.
R01 Clinical Trial Not Allowed: June 30, 2023; October 4, 2023; June 28, 2024; October 2, 2024.
|NIH||NIH New Models of Integrated HIV/AIDS, Addiction, and Primary Care Service||--||This supports the testing of enhanced models of care that optimally integrate HIV, addiction, and primary care services.|
- PAR-20-273 (R01 Clinical Trial Required): This seeks applications that will test comprehensive service delivery models. Applicants needing to develop, refine, and/or test key components of such a model are encouraged to apply to the companion R34.
- PAR-20-274 (R34 - Clinical Trial Optional): The R34 grant mechanism is intended to encourage planning research by providing support for the initial development of a clinical trial or research project.
|August 11, 2023.|
|NIH||NIH BRAIN Initiative: Transformative Brain Non-invasive Imaging Technology Development (UG3/UH3 Clinical Trial Not Allowed)||--||This is for team-centric development and validation of innovative non-invasive imaging technologies that could have a transformative impact on the study of brain function/connectivity. Applications are expected to turn a novel concept into a functional prototype using this phased grant mechanism.||October 13, 2023.|
|NIH||NIH Notice of Special Interest (NOSI): Validation of Digital Health and Artificial Intelligence Tools for Improved Assessment in Epidemiological, Clinical, and Intervention Research||--||This is to encourage grant applications to support the evaluation of the utility and validity of digital health and artificial intelligence (AI) tools and technologies in epidemiological, clinical, and intervention research. The intent is to support the addition of new measurement modalities to evaluate existing and recently developed but not yet validated digital health and AI tools such as sensor technologies, smartphone applications, software as a medical device (SaMD), and AI algorithms.||This Notice applies to due dates until March 9, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): Dissemination and Implementation Science for Cancer Prevention and Control in Low Resource Environments||--||and control in low- and middle-income countries. NCI encourages applications that pursue innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, tools, policies, and guidelines in low-resource settings.||This notice applies to subsequent receipt dates through May 8, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): Dissemination and Implementation Research to Advance Mental, Emotional, and Behavioral Health Preventive Interventions in School Settings||--||The purpose is to stimulate dissemination and implementation research to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based preventive interventions to support children's mental, emotional, and behavioral (MEB) health in school settings.||This Notice applies to due dates until June 5, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): Research on the Health of Sexual and Gender Minority (SGM) Populations||--||This encourages research that describes the biological, clinical, behavioral, and social processes that affect the health and development of SGM populations and individuals and their families, and that leads to the development of acceptable and appropriate health interventions and health service delivery methods that will enhance health and development of these populations.||This notice applies to subsequent receipt dates through August 1, 2025.|
|NIH||NIH BRAIN Initiative: Standards to Define Experiments Related to the BRAIN Initiative (R01 Clinical Trial Not Allowed)||--||This aims to develop standards that describe experimental protocols conducted as part of the BRAIN Initiative. It is expected that applications will solicit community input at all stages of the process. It is recommended that the first step of standard development will involve sharing data between different key groups in the experimental community in order to ensure that the developing standard will encompass the data collection efforts of those groups. The developed standard is expected to be broadly disseminated for use and widely available.||June 14, 2023; June 14, 2024.|
|NIH||NIH Behavioral Tasks Targeting Brain Systems Relevant to Anhedonia (R01 Basic Experimental Studies with Humans Required)||--||This encourages research to develop task-based behavioral measures that are shown to engage brain systems relevant to anhedonia using neuroimaging or other brain measures with similar spatial resolution. The goal is to identify behavioral tasks that can be used as quantitative tools in future studies of the functional constructs associated with anhedonia and in treatment development. This is for basic science experimental studies involving human participants that fall within the NIH definition of a clinical trial and also meet the definition of basic research.||Standard dates apply until September 8, 2023.|
|NIH||Occupational Safety and Health Research (R01) ||--||The purpose is (1) to develop an understanding of the risks and conditions associated with occupational diseases and injuries, (2) to explore methods for reducing risks and preventing or minimizing exposure to hazardous conditions in the workplace, and (3) to translate significant scientific findings into prevention practices and products that will effectively reduce work-related illnesses and injuries.||Standard dates apply until November 18, 2023.|
|NIH||NIH Notice of Special Interest (NOSI): Developing Digital Therapeutics for Substance Use Disorders||--||The National Institute on Drug Abuse (NIDA) seeks applications that stimulate research to support the development and testing of Digital Therapeutics (DTx) to treat Opioid Use Disorders (OUD) or Polysubstance Use Disorders (PUD) as stand-alone interventions or integrated with FDA-approved medication treatments.||This notice applies to subsequent receipt dates through December 7, 2023.|
|NIH||NIH Opportunities for Collaborative Research at the NIH Clinical Center (U01 Clinical Trial Optional)||--||This seeks to broaden and strengthen patient-centric translational research collaborations between basic and clinical researchers both within and outside NIH to accelerate and enhance translational science by promoting partnerships between NIH intramural investigators (e.g., those conducting research within the labs and clinics of the NIH) and extramural investigators (e.g., those conducting research in labs outside the NIH).||PAR-21-342: Pre-application (recommended, not required). Deadlines: December 13, 2022; December 13, 2023.
|NIH||NIH BRAIN Initiative: Brain Behavior Quantification and Synchronization (R61/R33 Clinical Trial Optional)||--||This supports the development and validation of next-generation tools, methods, and analytic approaches to precisely quantify behaviors and combine them with simultaneous recordings of brain activity in humans. Tools used for measuring and analyzing behavior should be multi-modal, with the appropriate accuracy, specificity, temporal resolution, and flexibility necessary for integration with existing tools used to measure and modulate the brain circuits that give rise to those behaviors.||February 17, 2023; February 15, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): Understanding the effects of cancer and cancer treatment on aging trajectories and aging outcomes||--||This supports applications that aim to better understand the effects of a cancer diagnosis and subsequent cancer treatment on aging trajectories and aging outcomes. These include, but are not limited to:|
- Investigation of aging trajectories associated with specific cancer treatments and identification of cancer survivors at risk for an "accelerated aging" phenotype;
- Examination of the effects of specific cancer treatments on aging biology that may alter aging trajectories or aging outcomes;
- Development and/or validation of tools, technologies, measures, or techniques for the identification of late-emerging effects and aging phenotypes among cancer survivors;
- Use of old and young animal models to determine the effects of established and newer cancer therapies on aging endpoints;
- Development and/or testing of interventions designed to prevent, mitigate or reverse the adverse aging-related effects of cancer and cancer treatments; and
- Development and/or testing of interventions focused on models and processes of care delivery to intervene at the intersection of cancer treatment and aging.
|This notice applies to receipt dates through January 7, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): Leveraging Real-World Imaging Data for Artificial Intelligence-based Modeling and Early Detection of Abdominal Cancers||--||This supports the secondary use of real-world data for Artificial Intelligence (AI)-based predictive modeling with the ultimate goal of improving early detection and risk assessment for abdominal cancers. This encourages applications proposing multi-institutional collaborative AI development approaches such as federated learning, which distributes the models to data-owners and aggregates the results without sharing the actual data.||This notice applies to subsequent receipt dates through January 8, 2024.|
|NIH||NIH Priority HIV/AIDS Research within the Mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (R01 Clinical Trial Optional) ||--||This seeks to stimulate HIV/AIDS research within the mission of the NIDDK that align with the HIV/AIDS research priorities outlined by the NIH Office of AIDS Research (OAR). These priorities were most recently described in NOT-OD-20-018 UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding.||Standard AIDS dates apply until January 8, 2024.|
|NIH||NIH Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (R21 Clinical Trial Not Allowed) ||--||This is for innovative basic and translational pilot research projects within the mission of the NIDDK that are aligned with NIH HIV/AIDS research priorities. These priorities were most recently described in NOT-OD-20-018 UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding. Potential topics could address multiple overarching priorities.||Standard AIDS dates apply until January 8, 2024.|
|NIH||Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)||--||This supports investigator-initiated clinical that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health.||Standard dates apply until January 8, 2024.|
|NIH||Notice of Special Interest (NOSI): Use of Predictive Analytics to Accelerate Late-Stage Implementation Research to Address Heart, Lung, Blood, and Sleep Disorders||--||National Heart, Lung, and Blood Institute (NHLBI) seeks to leverage existing data resources using Predictive Analytics Implementation Research (PAIR) that utilizes complex and innovative methodologies and modeling techniques to rely on integration of existing data to inform the designs (and often test) implementation strategies for heart, lung, blood, and sleep (HLBS) conditions. NHLBI also encourages applications which focus on the development of advance modeling techniques and data reporting, which would be publicly available and could be used to inform subsequent implementation strategies to address HLBS conditions.||This notice applies to receipt dates through January 8, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): Navigating Pediatric to Adult Health Care: Lost in Transition||-||This encourages applications in high-priority research areas related to pediatric health care transition for youth with chronic physical/medical conditions or intellectual/developmental disabilities. Research applications that will advance our understanding of promising practices designed to facilitate successful health care transitions (HCT) from pediatric to adult care settings as well as barriers and facilitators to such transition are encouraged.||This notice applies to subsequent receipt dates through January 8, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): Telehealth in Cancer Care||--||This supports investigator-initiated applications for conducting research on the use of telehealth in cancer-related care. Studies focused on populations that experience inequities in access to care and have worse cancer outcomes compared to the general population are strongly encouraged.||This notice applies to subsequent receipt dates through March 8, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): Validation of Digital Health and Artificial Intelligence Tools for Improved Assessment in Epidemiological, Clinical, and Intervention Research||--||This encourages grant applications to support the evaluation of the utility and validity of digital health and artificial intelligence (AI) tools and technologies in epidemiological, clinical, and intervention research. The intent is to support the addition of new measurement modalities to evaluate existing and recently developed but not yet validated digital health and AI tools such as sensor technologies, smartphone applications, software as a medical device (SaMD), and AI algorithms.||This notice applies to subsequent receipt dates through March 9, 2024.|
|NIH||NIH Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes||--||National Institute of Mental Health (NIMH) seeks applications to evaluate the preliminary effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions that are matched to the stage of illness in terms of both their focus and intensity/burden.|
PAR-21-211 (R34 Clinical Trial Required): This supports pilot research to evaluate the feasibility, tolerability, acceptability, safety and preliminary indications of effectiveness of post-acute phase intervention approaches and inform the design of definitive effectiveness trials.
PAR-21-210 (R01 Clinical Trial Required): This supports fully-powered, definitive effectiveness studies focused on post-acute phase interventions
|Standard dates apply until March 17, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): HIV Drug Resistance Assays and Actionable Data Dissemination Strategies||--||National Institute of Allergy and Infectious Diseases (NIAID) is interested in the development and optimization of next generation methodologies for HIV-1 drug resistance (DR) mutation detection and reporting. Strategies applicable to low and middle income countries as defined by the World Bank are especially encouraged.|
National Institute on Drug Abuse (NIDA) is interested in the following areas: Feasibility of self-administered, cost effective, and potential for mail-in testing and follow up through mobile technologies targeting substance-using populations living with HIV; Development of technologies that allow sensitive and rapid read out of drug resistance; Plans for post-administering surveys to assess rates of access, acceptability (stigma and ethical concerns), accuracy, and treatment outcomes; Technologies that are easily adaptable for implementation in homeless shelters, community clinics, criminal justice, and emergency department settings.
|This notice applies to subsequent receipt dates through May 7, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): Harnessing Big Data to Halt HIV||--||This is to promote and support innovative methods in Big Data Science (BDS) to identify unappreciated biomedical, behavioral, social patterns and other social determinants that shed light on HIV acquisition, transmission, the development of comorbidities, and long-term viral control as in the HIV treatment continuum. BDS approaches can bring together data to evaluate the complex interplay between individual, contextual, and structural factors influencing the epidemiology of risk and care. This NOSI will support the establishment of BDS standards, bioinformatics data tools, machine-learning algorithms, mathematical modeling, advanced epidemiology and statistical analytic methods, and consideration and application of privacy and ethical issues in the use of public and personal data in the context of HIV research.||This notice applies to subsequent receipt dates through May 7, 2024.|
|NIH||NIH Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional)||--||This supports exploratory and innovative research projects, which fall within the missions of the NINDS and NIMH. Awards will provide support for the early and conceptual stages of projects. These studies often assess the feasibility of a novel avenue of investigation and involve considerable risk, but have the potential to bring about breakthroughs in the understanding of important areas of neuroscience, or to the development of novel techniques, agents, methodologies, or models, of high value to the neuroscience community.||Standard dates apply until May 8, 2024.|
|NIH||NIH NIMH Exploratory/Developmental Research Grant (R21 Clinical Trial Not Allowed)||--||This supports exploratory and high-risk research projects that fall within the NIMH mission by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough or to the development of novel techniques, agents, methods, measures, models, or strategies, or to the generation of pilot or feasibility data.||Standard dates apply until May 8, 2024.|
|NIH||Notice of Special Interest (NOSI) regarding the Use of Human Connectome Data for Secondary Analysis||--||This encourages secondary analyses of data from the Human Connectome Project (HCP), including the multiple datasets in the Lifespan Human Connectome projects and the Human Connectomes Related to Human Disease. Applicants beyond the groups that originally collected the data are encouraged to apply. The analyses will serve to generate and evaluate hypotheses about the complex interrelationships among: brain structure, function and connectivity; cognitive, affective, sensory and motor processes; environmental factors; life event, social and psychosocial factors; genomic data, and clinical symptoms during development, aging, or disease.||This notice applies to receipt dates through May 8, 2024.|
|NIH||NIH Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD): Various Opportunities||Up to USD $50,000 per year for up to 2 years.|| PA-21-231 (R03 Basic Experimental Studies with Humans Required): This is for basic science experimental studies involving humans. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. |
PA-21-221 (R03 Clinical Trial Required): This supports clinical trials that fall within the NICHD mission.
|Standard dates apply until May 8, 2024.|
|NIH||NIH Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment||--||The purpose is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. Each partnership should include at least one academic and one industrial organization.|
PAR-21-166: R01 - Clinical Trial Not Allowed
PAR-21-206: R01 - Clinical Trial Optional
|Standard dates apply until May 8, 2024.|
|NIH||NIH Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity: Various Opportunities||--||The purpose of these Funding Opportunity Announcements (FOAs) is to lay the groundwork for developing interventions at the network/circuit level that might be used as potential treatments for cognitive, affective, or social deficits in psychiatric disorders. These FOAs support projects that test whether modifying electrophysiological patterns during behavior can improve cognitive, affective, or social processing.|
PAR-21-175 (R01 Clinical Trial Optional)
PAR-21-176 (R21 Clinical Trial Optional)
|Standard dates apply until May 8, 2024.|
|NIH||NIH Notice of Special Interest (NOSI) HIV/AIDS in the Era of COVID-19: When Pandemics Collide||--||This is to communicate special interest in epidemiology investigations to quantify the impact of the COVID-19 pandemic on HIV prevention, incidence, transmission, and outcomes. This NOSI encourages research on the impact and strategies needed to adapt the HIV/AIDS response through agile and innovative support of prevention and care and the maintenance of sustained HIV viral suppression during the COVID-19 pandemic.||This notice applies to due dates on or after September 7, 2021 and subsequent receipt dates through May 8, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): Promoting Vaccine Access, Acceptance and Uptake among Children, Adolescents, Pregnant and Lactating Women, and Persons with Disabilities||--||This NOSI encourages applications that address dimensions of access, acceptance and uptake of CDC-recommended vaccines among infants, children, adolescents, pregnant and lactating women, and persons with disabilities, especially among populations who are underserved or experience health disparities.||This notice applies to due dates on or after September 8, 2021 and subsequent receipt dates through May 8, 2024.|
|NIH||NIH Notice of Special Interest: Advancing Health Communication Research on HIV Prevention, Treatment and Cure||--||To address knowledge gaps that will improve HIV outcomes, this calls for research that will improve scientific understanding of health communication as it relates to ongoing HIV prevention, diagnosis, treatment and cure efforts, as well as research on communication, dissemination and implementation factors that are required for successful public understanding, acceptance and uptake of HIV-related interventions.||This notice applies to due dates on or after April 8, 2021 and subsequent receipt dates through May 8, 2024.|
|NIH||NIH Notice of Special Interest (NOSI) - Emerging and Existing Issues of Coronavirus Disease 2019 (COVID-19) Research Related to the Health and Well-Being of Women, Children and Individuals with Physical and/or Intellectual Disabilities||--||The purpose is to provide an avenue for researchers to pursue funding to conduct research addressing emerging and existing COVID-related issues among pregnant and lactating people, infants, children and adolescents, and individuals with physical and/or intellectual disabilities. Please see the NOSI for the areas of interest in these populations.||This notice applies to due dates on or after June 5, 2022 and subsequent receipt dates through June 6, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health||--||This calls for research grant applications that address patient adherence to treatment and prevention regimens to promote health outcomes. Applications may address healthcare regimen initiation, implementation, and/or persistence by patients. Descriptive and intervention research may address adherence determinants at one or more levels of ecologic influence, including the patient, caregiver/family, provider, healthcare system, and community levels.||This notice applies to subsequent receipt dates through June 8, 2024.|
|NIH||Notice of Special Interest (NOSI): The Influence of Host Resilience on Heterogeneity of Acute Respiratory Distress Syndrome/Acute Lung Injury (ARDS/ALI)||--||This NOSI seeks to support investigation into the factors and molecular mechanisms that address the heterogeneity dictated by the host resilience. Research on general host responses to injurious challenges and their effects on lung function as well as mechanisms that impact susceptibility to ARDS is not considered to be responsive to this announcement.||This notice applies to receipt dates through July 5, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): Using Data to Advance HIV Epidemic Knowledge and Program Planning||--||This encourages grant applications proposing research that makes use of available, large data sets with the objective of improving HIV epidemic modeling and service planning, with greater attention to the role of substance use. National Institute on Drug Abuse (NIDA) is interested in applications that make use of existing data, such as epidemiologic cohorts, clinic cohorts and longitudinal follow-up studies of interventions, as well as other publicly available sources of data including data warehouses and commercial data sources. Substance use should be a key component of any research supported by this NOSI.||This notice applies to subsequent receipt dates through September 7, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): Medical Consequences of Smoking and Vaping Drugs of Abuse in Individuals with HIV and COVID-19||--||National Institute on Drug Abuse (NIDA) is interested in receiving research applications focusing on individuals with HIV who smoke or vape marijuana, tobacco, cocaine and/or methamphetamine to determine the long-term effects of their use among individuals with HIV and COVID-19.||This notice applies to due dates through September 7, 2024.|
|NIH||Notice of Special Interest (NOSI): Effects of smoking and vaping on the risk and outcome of COVID-19 infection||--||This NOSI encourages research to understand: |
- The risks that smoking or vaping tobacco or marijuana may have on acquiring the COVID-19 infection.
- The medical consequences, co-morbidity, and complications of COVID-19 infection in individuals who smoke or vape tobacco or marijuana.
- The medical consequences of COVID-19 in individuals who smoke and vape with comorbid conditions such as: SUD, HIV and other immunosuppressive diseases, mental health disorders, diabetes mellitus, obesity, cardiovascular, pulmonary, renal, and hepatic pathologies, as well as cancer.
|This notice applies to due dates through September 8, 2024.|
|NIH||NIH Basic Research in Cancer Health Disparities||--||This encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities.|
- R01 Clinical Trial Not Allowed: These research project grants will support innovative studies designed to investigate biological/genetic bases of cancer health disparities.
- R21 Clinical Trial Not Allowed: This provides support for early-stage exploratory projects that lead to future in-depth mechanistic studies (such as R01 projects) of the biology of cancer health disparities.
- R03 Clinical Trial Not Allowed These small research grants will support projects on cancer health disparities that can be carried out in a short period of time with limited resources.
|Standard dates apply until September 8, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): Behavioral Economics for Implementation Research (BEIR) to improve use of Evidence-Based Practices for heart, lung, blood, and sleep (HLBS) conditions||--||National Heart, Lung, and Blood Institute (NHLBI) encourages applications that recognize the importance of cultural context, patterns of behavior change, and motivators for change across decision-making levels, including individuals (e.g., patients, parents, clinicians, others), groups, healthcare systems and/or communities.||This notice applies to subsequent receipt dates through September 8, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): International Research Collaboration on Drug Abuse and Addiction Research||--||The purpose of this notice is to encourage collaborative research applications that take advantage of opportunities outside of the US. Applications examining all areas of National Institute on Drug Abuse (NIDA)-supported research addressing the causes, consequences, treatment, and prevention of drug use, misuse, and addiction are encouraged. Projects should be conducted through newly formed or well-established partnerships between an investigator in a US-based institution and a scientist working in another country.||This notice applies to subsequent receipt dates through September 8, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): Research on Interprofessional Teamwork and Coordination During Cancer Diagnosis and Treatment||--||The purpose is to stimulate research that identifies effective strategies for improving interprofessional teamwork and addresses care coordination challenges within care settings and between care settings (e.g., between tertiary care and community settings) or during care transitions (e.g., from inpatient to outpatient care). Research in this area should advance actionable knowledge about how to design and carry out effective, efficient interprofessional team-based cancer care that improves quality and patient outcomes. Research that is focused on the needs of racial/ethnic minority, medically underserved, or low-income populations and/or those receiving care in community settings (including, but not limited to, community-based cancer centers or clinics) is not required, but strongly encouraged.||This notice applies to subsequent receipt dates through October 9, 2024.|
|NIH||NIH Clinical Trial Readiness for Functional Neurological Disorders (FNDs) (U01 Clinical Trial Optional)||--||This invites researchers to submit prospective clinical projects that address critical needs for clinical trial readiness in FNDs. Projects appropriate for this funding opportunity announcement include the validation of biomarkers, endpoints and clinical outcome assessments that are fit-for-purpose and have a defined context of use for clinical trials||Standard dates apply until November 6, 2024.|
|NIH||NIH Neuromodulation/Neurostimulation Device Development for Mental Health Applications||--||This encourages applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are encouraged that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently FDA-approved or cleared.|
- R01 Clinical Trial Not Allowed: For applicants who seek to propose a larger project. Applicants who seek to establish proof-of-concept should respond to the companion R21.
-R21 Clinical Trial Not Allowed: This uses the R21 grant mechanism, encouraging shorter, higher-risk applications. Applications that seek to study scientific or clinical hypotheses that simply utilize devices are outside the scope.
|Standard dates apply until January 8, 2025.|
|NIH||NIH - Notice of Special Interest (NOSI): Research on the Impact of Policy Changes and Emerging and Evolving Public Health Crises on NICHD Populations of Interest||--||This aims to study the effect of emerging and evolving public health crises and/or policy changes on the health, development, and well-being of populations of interest to the NICHD: neonates, infants, children, adolescents, and young adults, pregnant and post-partum and nursing people, individuals of reproductive age, and individuals with intellectual, developmental, or physical disabilities, as well as the families of these individuals.||This notice applies to subsequent receipt dates through January 8, 2025.|
|NIH||NIH Drug Discovery for Nervous System Disorders||--||NIMH, NIAAA, NIDA and NIA wish to stimulate research in: 1) Identification, design, synthesis, and preclinical testing of small molecules for their potential as candidate therapeutics ; 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest; 3) Later stage lead optimization to improve efficacy and pharmacokinetics; and 4) Initial drug metabolism and pharmacokinetic properties (DMPK). Emphasis will be placed on projects that provide novel approaches for identifying potential therapeutic agents.|
- R01 Clinical Trials Not Allowed: Applicants with preliminary data may wish to apply using the R01 mechanism. High risk/high payoff projects that lack preliminary data may be most appropriate for the R21 mechanism.
- R21 Clinical Trials Not Allowed: This will also support applications proposing preclinical discovery of biotechnology products and biologics with potential as candidate therapeutics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies).
|Standard dates apply until January 8, 2025.|
|NIH||NIH Notice of Special Interest (NOSI): COVID-19 Pandemic Mental Health Research||--||National Institute of Mental Health (NIMH) is issuing this NOSI to highlight interest in basic, translational, intervention and services research relevant to the COVID-19 pandemic. NIMH is especially interested in research to provide an evidence base to understand how mental illness contributes to COVID-19 risk and mortality, how incident mental illness develops with COVID-19, and the development of scalable interventions to meet the public mental health needs during and resulting from the pandemic both specifically related to the virus but also at a broader population level that is impacted by stress, disruptions, and loss of lives in the pandemic. Research addressing the intersection of COVID-19, mental health, and HIV treatment and prevention are also of interest to NIMH. Research is anticipated to focus on particularly vulnerable populations based on existing evidence of increased mental health symptoms and illness and preexisting and worsening health disparities.||This Notice applies to subsequent receipt dates through January 8, 2025.|
|NIH||NIH Notice of Special Interest (NOSI): Public Health Research on Cannabis||--||The National Institute on Drug Abuse (NIDA) is issuing this notice to encourage grant applications on the effects of changing cannabis laws and policies in the US and globally on public health.||This notice applies to subsequent receipt dates through May 5, 2025.|
|NIH||NIH Laboratories to Optimize Digital Health (R01 Clinical Trial Required)||--||This is intended to support the development of digital health test beds that leverage well-established digital mental health platforms and infrastructure to rapidly refine and optimize existing evidence-based digital health interventions and to conduct clinical research testing digital mental health interventions that are statistically powered to provide a definitive answer regarding the intervention's effectiveness particularly in populations who experience health disparities and vulnerable populations.||Standard dates apply until May 8, 2025.|
|NIH||NIH Notice of Special Interest (NOSI): Addressing Evidence Gaps in Screening||--||This encourages applications proposing to test multilevel strategies and interventions to improve the uptake of evidence-based screening services across the lifespan and in populations including, but not limited to, those experiencing health disparities and those that are underserved. Studies addressing efficacy, effectiveness, dissemination and implementation research, as well as studies seeking to understand and address barriers to screening are encouraged.||This NOSI applies to subsequent receipt dates through May 8, 2025.|
|NIH||NIH Notice of Special Interest (NOSI): Research to Prevent Drug Use, Misuse and Addiction||--||The National Institute on Drug Abuse (NIDA) is issuing this Notice to encourage grant applications in research on the prevention of risky drug use behaviors and addiction. The research may include studies to: 1) develop and test strategies to prevent the initiation of substance use, progression to substance use disorders, or to prevent substance use-related conditions such as HIV; 2) develop and test processes or strategies to implement, scale, and sustain evidence-based prevention in community, practice, and service systems;and,3) develop methods to conduct prevention science. Primary outcomes of interest for submitted applications include preventing initiation of substance use, misuse, and progression to disorder, as well as prevention of HIV infection.||This notice applies to subsequent receipt dates through May 8, 2025.|
|NIH||NIH Notice of Special Interest (NOSI): Addressing Evidence Gaps in Screening||--||This is to solicit applications proposing to strengthen the evidence base for preventive screening services where the evidence is lacking, of poor quality, conflicting, or the balance of benefits and harms cannot be determined. It encourages the development and use of innovative and rigorous methods and approaches to close high priority evidence gaps to elevate screening services to a level suitable for a definitive grade or recommendation.||This NOSI applies to subsequent receipt dates through May 8, 2025.|
|NIH||NIH Notice of Special Interest (NOSI): Addressing Evidence Gaps in Screening||--||This encourages translational research aimed at filling identified knowledge gaps to expand the evidence base for evaluating the balance of benefits and harms for proposed preventive screenings. At minimum, the proposed study must: Focus on a screening service that has not received a definitive grade or recommendation from organizations issuing evidence-based recommendations; and, include a measurable health outcome.||This notice applies to subsequent receipt dates through May 8, 2025.|
|NIH||NIH Notice of Special Interest (NOSI): Increasing Uptake of Evidence-Based Screening in Diverse Populations Across the Lifespan||--||This encourages highly innovative translational research focused on the delivery of multilevel interventions to improve uptake of evidence-based screening services that promote health equity and that are recommended by expert committees. At minimum, the proposed studies must: Include screening as a primary outcome; Inform the development of OR test an intervention or strategy that acts on at least two socioecological levels; and, Include OR test an intervention or strategy that demonstrates high potential for scalability and sustainability.||This notice applies to subsequent receipt dates through May 8, 2025.|
|NIH||NIH NEI Research Grant for Vision-Related Secondary Data Analysis (R21 Clinical Trial Not Allowed)||--||The purpose is for secondary data analysis using existing data sets from vision-related clinical trials, epidemiologic, and other clinical research studies. This may be used to develop new statistical methodologies or test hypotheses using existing data, but must not be used to support the collection of new data.||Standard dates apply until May 8, 2025.|
|NIH||NIH NEI Clinical Research Study Planning Grant Program (R34 Clinical Trial Not Allowed)||--||This supports applicants in their planning efforts to conduct collaborative large-scale clinical vision research projects, including randomized clinical trials and epidemiologic studies on eye/vision conditions. The grant may be used to support the development of a Manual of Procedures (MOP), as well as to conduct preliminary studies to refine study procedures or document recruitment potential. The grant must not be used to generate data on the effects of a proposed intervention.||Standard dates apply until May 8, 2025.|
|NIH||NIH Innovative Pilot Mental Health Services Research Not Involving Clinical Trials (R34 Clinical Trial Not Allowed)||--||This encourages innovative pilot research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. This announcement invites applications for non-clinical trial pilot projects that address National Institute of Mental Health (NIMH) strategic priorities to strengthen the public health impact of NIMH-supported research as described in Goal 4 of the NIMH Strategic Plan.||Standard due dates apply until May 8, 2025.|
|NIH||NIH HEAL Initiative Notice of Special Interest (NOSI): Development and Validation of Pain-Related Models and Endpoints to Facilitate Non-Addictive Analgesic Discovery||--||This is to encourage the development, validation, and replication of animal models that recapitulate the phenotypic and physiologic characteristics of a defined pain type/indication and/or disease-associated pain condition and endpoints or outcome measures that can be used therein.||This notice applies to subsequent receipt dates through June 25, 2025.|
|NIH||NIH Notice of Special Interest (NOSI): Diagnostics and Disease Management Tools for Use in Underserved Populations||--||This seeks applications for diagnostics and disease management tools that have the power to deliver breakthroughs to enable prevention and treatment of heart, lung, blood and sleep diseases in underserved communities. Investigators will be required to engage community partners at the onset and throughout their research project.||This notice applies to subsequent receipt dates through July 6, 2025.|
|NIH||NIH Notice of Special Interest (NOSI): Studies of Cellular/Molecular Pathobiological Mechanisms of Lung Diseases Using Human 3-Dimensional Cellular Systems (R01)||--||This promotes research characterizing the pathobiological processes and mechanisms that drive the onset and progression of lung diseases at a molecular/cellular level, providing a systems-level understanding by studying experimental systems with cellular heterogeneity and 3-D architecture. Projects will utilize ex vivo preparations (e.g., thin human lung slices) or 3-D multi-cellular in vitro systems (e.g., organoids) of human lung cells and will employ state-of-art multi-omics measures (e.g., spatial or single cell/nucleus omics).||This notice applies to subsequent receipt dates through September 7, 2025.|
|NIH||NIH: Notice of Special Interest (NOSI): Preventive Interventions to Address Cardiometabolic Risk Factors in Populations that Experience Health Disparities||--||The purpose of this NOSI is to solicit projects on preventive interventions that address cardiometabolic risk factors in populations that experience health disparities.||This notice applies to subsequent receipt dates through September 8, 2025.|
|NIH||NIH Notice of Special Interest (NOSI): Epidemiology of Drug Abuse||--||This encourages the submission of research project applications that enhance our understanding of the nature, extent, distribution, etiology, comorbidities, and consequences of drug use, misuse, and addiction across individuals, families, communities, and diverse population groups. Of interest are applications that address multiple levels of risk, resilience, and causation across scientific disciplines, and that apply novel methods to advance knowledge of the interplay among genetic, environmental, neurobiological, and developmental factors and associated health and disease outcomes.||This notice applies to subsequent receipt dates through September 8, 2025.|
|NIH||NIH Bioengineering Research Grants (BRG)||--||This is to encourage collaborations- between life science and physical science- that: 1) apply a multidisciplinary bioengineering approach to solve biomedical problems; and 2) develop, integrate, optimize, validate, translate or accelerate adoption of promising tools, methods and techniques: a) that fulfill an unmet need and address specific research or clinical problem in basic, translational, and/or clinical science and practice, b) capable of enhancing our understanding of health and disease, and/or c) improve practice of medicine.|
R01 Clinical Trial Not Allowed: This is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical or translational science.
R01 Clinical Trial Optional: This will support clinical trials that test functionality or validate performance in the chosen setting.
|Standard due dates apply until September 8, 2025|
|NIH||NIH Notice of Special Interest (NOSI): Leveraging Data Science to Bring Actionable Insights for Substance Use Prevention and Treatment||--||This supports research projects that 1) leverage data science to provide actionable insights for substance use prevention and treatment, 2) shorten the time between data capture and data availability so that data are available real-time or near real-time, and 3) explore methods and tools that may allow for faster or better localized responses for substance use treatment and prevention. Priority will be given to projects that emphasize the use of existing data streams (e.g., electronic health records, syndromic surveillance, claims data, registry data, pharmacy dispensing, social media, and mortality records).||This notice applies to subsequent receipt dates through September 8, 2025.|
|NIH||NIH Notice of Special Interest (NOSI): Development and Implementation of Clinical Informatics Tools to Enhance Patients' Use of Genomic Information||--||This encourages applications to develop and implement patient-facing genomic-based clinical informatics tools that facilitate or enhance patient-provider electronic communication, patient tracking and registry functions, patient self-management and support, provider electronic prescribing, test tracking, referral tracking, and health care decision-making.||This notice applies to subsequent receipt dates through September 24, 2025.|
|NIH||NIH Notice of Special Interest (NOSI): Research on Addressing Violence to Improve Health Outcomes||--||This encourages novel intervention research aimed at developing, refining, adapting, and testing interventions focused on preventing violence or addressing acute and chronic effects of violence on physical and behavioral health. Effectiveness, implementation, and hybrid effectiveness-implementation designs are encouraged, as appropriate to the research questions proposed.||This notice applies to subsequent receipt dates through October 5, 2025.|
|NIH||NIH Notice of Special Interest (NOSI): Promoting Cardiovascular and Cardiometabolic Health in Early Stages of the Lifecourse: Pre-adolescence Through Adolescence to Young Adulthood||--||This supports support research to: 1) understand the mechanisms and the pathogenesis of cardiometabolic health and cardiovascular disease (CVD) risk in vulnerable groups throughout transitionary phases, from pre-adolescence (6-10 years) through adolescence (11-18 years) to young adulthood (19-39 years), and 2) develop precision prevention interventions (at the individual and populations levels) to address cardiovascular and cardiometabolic risk across these transitionary phases.||This notice applies to subsequent receipt dates through June 5, 2026.|
|NIH||NIH Parent Announcements||--||- NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)|
- NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- NIH Research Project Grant (Parent R01 Clinical Trial Required)
- NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)
|Standard dates apply unless otherwise stated.|